Vascular Solutions 10-K 3 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Jan. 26, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	VASCULAR SOLUTIONS INC
Entity Central Index Key	1030206
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$363,913,626
Entity Common Stock, Shares Outstanding		17,201,990
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$36,461,000	$30,785,000
Accounts receivable, net of reserves of $300,000 and $200,000 at December 31, 2014 and 2013, respectively	17,105,000	14,481,000
Inventories	15,908,000	14,002,000
Prepaid expenses and other	5,231,000	2,472,000
Current portion of deferred tax assets	3,681,000	6,000,000
Total current assets	78,386,000	67,740,000
Property, plant and equipment, net	25,665,000	16,187,000
Goodwill	10,259,000	10,532,000
Intangible assets, net	10,164,000	11,943,000
Deferred tax assets, net of current portion and liabilities	2,894,000	1,739,000
Total assets	127,368,000	108,141,000
Current liabilities:
Accounts payable	4,806,000	3,762,000
Accrued compensation	4,580,000	4,365,000
Accrued expenses	3,016,000	2,467,000
Accrued royalties	230,000	235,000
Current portion of deferred revenue and contingent consideration	391,000	556,000
Total current liabilities	13,023,000	11,385,000
Long-term deferred revenue, net of current portion	202,000	406,000
Long-term deferred tax liabilities	803,000	0
Total long-term liabilities	1,005,000	406,000
Commitments and contingencies
Shareholders' equity:
Common stock, $0.01 par value: Authorized shares - 40,000,000 Issued and outstanding shares - 17,202,365 - 2014; 16,964,953 - 2013	172,000	170,000
Additional paid-in capital	97,324,000	92,346,000
Other	-725,000	-1,000
Accumulated earnings	16,569,000	3,835,000
Total shareholders' equity	113,340,000	96,350,000
Total liabilities and shareholders' equity	$127,368,000	$108,141,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Reserves for accounts receivable	$300,000	$200,000
Shareholders' equity:
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	17,202,365	16,964,953
Common stock, shares outstanding (in shares)	17,202,365	16,964,953

Consolidated_Statements_of_Ear

Consolidated Statements of Earnings (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net revenue
Product revenue	$125,666,000	$110,197,000	$98,036,000
License royalty and collaboration revenue	433,000	301,000	350,000
Total revenue	126,099,000	110,498,000	98,386,000
Product costs and operating expenses:
Cost of goods sold	41,699,000	36,156,000	32,561,000
Collaboration expenses	165,000	60,000	0
Research and development	13,441,000	13,191,000	11,870,000
Clinical and regulatory	4,979,000	4,408,000	4,358,000
Sales and marketing	29,825,000	27,372,000	25,777,000
General and administrative	12,986,000	8,991,000	6,522,000
Litigation settlement	0	1,332,000	0
Medical device excise taxes	1,435,000	1,319,000	0
Amortization of purchased technology and intangibles	1,642,000	1,572,000	1,393,000
Total product costs and operating expenses	106,172,000	94,401,000	82,481,000
Operating earnings	19,927,000	16,097,000	15,905,000
Other expenses	-15,000	-14,000	-13,000
Earnings before income taxes	19,912,000	16,083,000	15,892,000
Income tax expense	-7,178,000	-4,941,000	-5,983,000
Net earnings	$12,734,000	$11,142,000	$9,909,000
Basic net earnings per common share (in dollars per share)	$0.75	$0.68	$0.62
Diluted net earnings per common share (in dollars per share)	$0.72	$0.65	$0.60
Shares used in computing basic net earnings per common share (in shares)	16,891,643	16,412,322	16,003,932
Shares used in computing diluted net earnings per common share (in shares)	17,710,562	17,025,090	16,455,729

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Earnings (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Comprehensive Earnings [Abstract]
Net earnings	$12,734,000	$11,142,000	$9,909,000
Other comprehensive earnings (loss), net of tax of $0: Foreign currency translation adjustments	-724,000	149,000	54,000
Total comprehensive earnings	$12,010,000	$11,291,000	$9,963,000

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Earnings (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Comprehensive Earnings [Abstract]
Foreign currency translation adjustments, tax	$0	$0	$0

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Shareholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Other [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2011	$164,000	$83,962,000	($204,000)	($17,216,000)	$66,706,000
Balance (in shares) at Dec. 31, 2011	16,378,205
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	2,000	487,000	0	0	489,000
Exercise of stock options (in shares)	157,590
Issuance of common stock under the Employee Stock Purchase Plan	1,000	1,003,000	0	0	1,004,000
Issuance of common stock under the Employee Stock Purchase Plan (in shares)	114,060
Stock-based compensation	2,000	2,981,000	0	0	2,983,000
Stock-based compensation (in shares)	213,309
Repurchase and cancellation of common stock upon the vesting of restricted shares	-1,000	-651,000	0	0	-652,000
Repurchase and cancellation of common stock upon the vesting of restricted shares (in shares)	-59,106
Repurchase of common stock under stock repurchase agreement	-4,000	-4,757,000	0	0	-4,761,000
Repurchase of common stock under stock repurchase agreement (in shares)	-425,135
Tax benefit from stock-based awards	0	1,135,000	0	0	1,135,000
Comprehensive earnings:
Net earnings	0	0	0	9,909,000	9,909,000
Translation adjustment	0	0	54,000	0	54,000
Total comprehensive earnings					9,963,000
Balance at Dec. 31, 2012	164,000	84,160,000	-150,000	-7,307,000	76,867,000
Balance (in shares) at Dec. 31, 2012	16,378,923
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	4,000	2,780,000	0	0	2,784,000
Exercise of stock options (in shares)	354,300
Issuance of common stock under the Employee Stock Purchase Plan	1,000	1,191,000	0	0	1,192,000
Issuance of common stock under the Employee Stock Purchase Plan (in shares)	124,098
Stock-based compensation	2,000	3,341,000	0	0	3,343,000
Stock-based compensation (in shares)	183,034
Repurchase and cancellation of common stock upon the vesting of restricted shares	-1,000	-1,210,000	0	0	-1,211,000
Repurchase and cancellation of common stock upon the vesting of restricted shares (in shares)	-75,402
Tax benefit from stock-based awards	0	2,084,000	0	0	2,084,000
Comprehensive earnings:
Net earnings	0	0	0	11,142,000	11,142,000
Translation adjustment	0	0	149,000	0	149,000
Total comprehensive earnings					11,291,000
Balance at Dec. 31, 2013	170,000	92,346,000	-1,000	3,835,000	96,350,000
Balance (in shares) at Dec. 31, 2013	16,964,953				16,964,953
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	1,000	970,000	0	0	971,000
Exercise of stock options (in shares)	102,000
Issuance of common stock under the Employee Stock Purchase Plan	1,000	1,434,000	0	0	1,435,000
Issuance of common stock under the Employee Stock Purchase Plan (in shares)	103,467
Stock-based compensation	1,000	3,881,000	0	0	3,882,000
Stock-based compensation (in shares)	165,911
Repurchase and cancellation of common stock upon the vesting of restricted shares	-1,000	-2,311,000	0	0	-2,312,000
Repurchase and cancellation of common stock upon the vesting of restricted shares (in shares)	-100,565
Repurchase of common stock under stock repurchase agreement	0	-819,000	0	0	-819,000
Repurchase of common stock under stock repurchase agreement (in shares)	-33,401
Tax benefit from stock-based awards	0	1,823,000	0	0	1,823,000
Comprehensive earnings:
Net earnings	0	0	0	12,734,000	12,734,000
Translation adjustment	0	0	-724,000	0	-724,000
Total comprehensive earnings					12,010,000
Balance at Dec. 31, 2014	$172,000	$97,324,000	($725,000)	$16,569,000	$113,340,000
Balance (in shares) at Dec. 31, 2014	17,202,365				17,202,365

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net earnings	$12,734,000	$11,142,000	$9,909,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	3,257,000	2,861,000	2,158,000
Amortization	1,642,000	1,572,000	1,393,000
Stock-based compensation	3,882,000	3,343,000	2,983,000
Deferred taxes, net	1,971,000	3,138,000	5,287,000
Tax benefit from stock-based awards	-1,823,000	-2,084,000	-1,135,000
Loss (gain) on disposal of fixed assets	-24,000	-17,000	6,000
Change in fair value of contingent consideration	0	-79,000	-232,000
Change in accounts receivable allowance	100,000	15,000	35,000
Changes in operating assets and liabilities:
Accounts receivable	-2,741,000	-713,000	-2,084,000
Inventories	-1,909,000	-435,000	1,032,000
Prepaid expenses and other	-948,000	158,000	-977,000
Accounts payable	1,086,000	-86,000	995,000
Accrued compensation and expenses	622,000	485,000	192,000
Amortization of deferred license fees and other deferred revenue	-370,000	86,000	-351,000
Net cash provided by operating activities	17,479,000	19,386,000	19,211,000
Investing activities
Purchase of property and equipment, net	-5,681,000	-4,234,000	-3,145,000
Purchase of building and land	-7,123,000	0	-7,986,000
Proceeds from the sale of equipment	28,000	22,000	10,000
Cash paid for acquisitions	0	-820,000	-7,500,000
Net cash used in investing activities	-12,776,000	-5,032,000	-18,621,000
Financing activities
Net proceeds from the exercise of stock options	971,000	2,784,000	489,000
Net proceeds from the sale of common stock, employee stock purchase plan	1,435,000	1,192,000	1,004,000
Tax benefit from stock-based awards	1,823,000	2,084,000	1,135,000
Repurchase of common shares	-3,131,000	-1,211,000	-5,413,000
Net cash provided by (used in) financing activities	1,098,000	4,849,000	-2,785,000
Effect of exchange rate changes on cash and cash equivalents	-125,000	28,000	23,000
Increase (decrease) in cash and cash equivalents	5,676,000	19,231,000	-2,172,000
Cash and cash equivalents at beginning of year	30,785,000	11,554,000	13,726,000
Cash and cash equivalents at end of year	36,461,000	30,785,000	11,554,000
Supplemental disclosure of cash flow
Cash paid for interest	3,000	13,000	13,000
Cash paid for federal and state income taxes	$3,769,000	$1,673,000	$902,000

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2014
Description of Business [Abstract]
Description of Business	1. Description of Business
	Vascular Solutions, Inc. (the Company) is a medical device company focused on bringing clinically advanced solutions to interventional cardiologists and interventional radiologists.  The Company has three product categories as follows:
		·	Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner® catheter used to access discrete regions of the coronary anatomy and the Pronto® extraction catheters used in treating acute myocardial infarction.  This category also includes products used in connection with gaining percutaneous access to the vasculature to perform minimally invasive procedures, such as micro-introducer kits.
		·	Hemostat products consist principally of blood clotting products, such as the D-Stat® Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets.  This category also includes our line of devices used in radial artery procedures, such as our Accumed™ wrist positioning splints and Vasc™ Band inflatable compression bands.
		·	Vein products and services consist principally of the Vari-Lase® endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST® radiofrequency vein ablation catheter.
	As a vertically-integrated medical device company, the Company generates ideas and creates new minimally invasive devices or services and then delivers these products and services to the physicians through a direct domestic sales force and an international distribution network.  The Company was incorporated in the state of Minnesota in December 1996 and began operations in February 1997.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Basis of Consolidation
	The consolidated financial statements include the accounts of Vascular Solutions, Inc. and its wholly-owned subsidiary Vascular Solutions Zerusa Limited, after elimination of intercompany accounts and transactions.
	Segment Reporting
	A business segment is a distinguishable component of an enterprise that is engaged in providing an individual product or service or a group of related products or services and that is subject to risks and returns that are different from those of other business segments.  The Company’s segments have similar economic characteristics and are similar in the nature of the products sold, type of customers, methods used to distribute the Company’s products and regulatory environment.  Management believes that the Company meets the criteria for aggregating its operating segments into a single reporting segment.
	The Company uses three product categories for reporting revenue.  The following table sets forth, for the periods indicated, net revenue by product category along with the percent change from the previous year:
			For Years Ended December 31,
			2014						2013						2012
			Net Revenue			Percent Change			Net Revenue			Percent Change			Net Revenue		Percent Change
	Catheter products		$	82,885,000			19	%	$	69,936,000			14	%	$	61,262,000		16	%
	Hemostat products			24,389,000			3	%		23,752,000			5	%		22,676,000		(2	%)
	Vein products			18,392,000			11	%		16,509,000			17	%		14,098,000		34	%
	Total product revenue			125,666,000			14	%		110,197,000			12	%		98,036,000		13	%
	License, royalty & collaboration			433,000			44	%		301,000			(14	%)		350,000		(90	%)
	Total Net Revenue		$	126,099,000			14	%	$	110,498,000			12	%	$	98,386,000		9	%
	Foreign Currency Translation and Transactions
	The functional currency of the company's foreign operations is the applicable local currency.  The functional currency is translated into U.S. dollars for balance sheet accounts using current exchange rates in effect as of the balance sheet date and for revenue and expense accounts using a weighted-average exchange rate during the fiscal year.  The translation adjustments are deferred as a component of other comprehensive income within the consolidated statements of comprehensive income and the consolidated statements of shareholders’ equity.  Gains or losses resulting from transactions denominated in foreign currencies are included in other income, net in the consolidated statements of earnings.
	The Company sells products to an international distributor in Germany at prices denominated in Euros.  As a result, the Company is exposed to foreign exchange movements during the time between the shipment of the product and payment.  The Company currently has terms of net 60 days with this distributor under the agreement providing for payment in Euros.
	Comprehensive Earnings
	The components of comprehensive earnings are net earnings and the effects of foreign currency translation adjustments.  The accumulated other comprehensive earnings for the foreign currency translation adjustment at December 31, 2014 and 2013 was ($725,000) and ($1,000), respectively.
	Fair Value of Financial Instruments
	The carrying amount for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximates fair value due to the immediate or short-term maturity of these financial instruments.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of deferred tax assets and liabilities, as well as other amounts in the financial statements and accompanying notes.  Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company classifies all highly liquid investments with initial maturities of three months at the date of purchase or less as cash equivalents.  Cash equivalents consist of cash and money market funds and are stated at cost, which approximates market value.  The Company deposits its cash in high quality financial institutions.  The balances, at times, may exceed federally insured limits.
	Credit Risk and Allowance for Doubtful Accounts
	The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments.  This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay.  Accounts receivable over 60 days past due are considered past due.  The Company does not accrue interest on past due accounts receivable.  Receivables are written off only after all collection attempts have failed and are based on individual credit evaluation and the specific circumstances of the customer.  At December 31, 2014 and 2013, the allowance for doubtful accounts was $220,000 and $150,000, respectively.
	All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.  The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on its balance sheet.  At December 31, 2014 and 2013, the sales and return allowance was $80,000 and $50,000, respectively.
	Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $300,000 and $200,000 at December 31, 2014 and 2013, respectively.
	Inventories
	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.   Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following at December 31:
			2014			2013
	Raw materials		$	8,251,000		$	6,386,000
	Work-in-process			1,139,000			926,000
	Finished goods			6,518,000			6,690,000
			$	15,908,000		$	14,002,000
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost.  Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Manufacturing equipment	1 to 8 years
	Office and computer equipment	1 to 5 years
	Furniture and fixtures	3 to 8 years
	Leasehold improvements	Shorter of useful life or remaining term of the lease
	Research and development equipment	3 to 7 years
	Building improvements	1 to 30 years
	Building	30 years
	Impairment of Long-Lived Assets
	The Company will record impairment losses on long-lived assets when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount.  The amount of impairment loss recorded will be measured as the amount by which the carrying value of the assets exceeds the fair value of the assets.  To date, the Company has determined that no impairment of long-lived assets exists.
	Revenue Recognition
	In the United States, the Company sells its products and services directly to hospitals and clinics.  Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers.   The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.
	In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics.  The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor. The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor.  Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order and is reported on a gross basis.  Allowances are provided for estimated returns and costs at the time of shipment.  Sales and use taxes are reported on a net basis, excluding them from revenue.
	The Company’s revenues from license agreements and research collaborations are recognized when earned (see Note 14).  In accordance with ASC 605, for revenues which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller.  Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit.  Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC 605.
	The Company currently has a license agreement with King Pharmaceuticals, Inc. (King), now a subsidiary of Pfizer, Inc., under which the Company licensed the exclusive rights of Thrombi-Pad®, Thrombi-Gel® and Thrombi-Paste TM products to King in exchange for a license fee.  The Company is amortizing the license fees on a straight-line basis over the projected 10 year economic life of the products.  The Company determines the economic life of the products under its license agreements by evaluating similar products the Company has launched or other similar products in the medical industry.  In addition, the Company had a five-year license agreement with Nicolai, GmbH in which the Company was amortizing the license fee on a straight-line basis over the five-year life of the agreement.  This agreement was fully amortized during 2013.
	Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFAST radiofrequency catheters.  In accordance with ASC 605-45, the Company recognizes this revenue gross, with the amount paid to the supplier of the reprocessing service reflected as cost of sales.
	In addition, the Company has reviewed the provisions of ASC 808, Collaborative Arrangements, and the adoption of this ASC has had no impact on the amounts recorded under these agreements.
	In May 2014, the Financial Accounting Standards Board (FASB) issued guidance creating ASC 606, “Revenue from Contracts with Customers.”  The new section will replace ASC 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries.  The new ASC is intended to conform United States revenue accounting principles with concurrently issued International Financial Reporting Standards.  Prior to the guidance, revenue recognition differed between United States practice and those of much of the rest of the world.  The guidance also is intended to enhance disclosures related to disaggregated revenue information.  The updated guidance is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods.  The Company will adopt the new provisions of this accounting standard at the beginning of fiscal year 2017, given that early adoption is not an option.  The Company does not expect adoption will have an impact on the consolidated financial statements.
	Shipping and Handling Costs
	In accordance with the ASC 605-45-45, the Company includes shipping and handling revenues in net revenue and shipping and handling costs in cost of goods sold.
	Research and Development Costs
	All research and development costs are charged to operations as incurred.
	Warranty Costs
	Certain of the Company’s products are covered by warranties against defects in material and workmanship for periods of up to 24 months.  The Company records a liability for warranty claims at the time of sale.  The amount of the liability is based on the amount the Company is charged from its original equipment manufacturer to cover the warranty period.  The original equipment manufacturers include a one year warranty with each product sold to the Company.  The Company records a liability for the uncovered warranty period offered to a customer, provided the warranty period offered exceeds the initial one year warranty period covered by the original equipment manufacturers.  Each of the Company’s manufacturer’s warranties covers the first year of service and as a result the Company’s exposure to uncovered warranty periods was minimal at December 31, 2014.
	Warranty provisions and claims for the years ended December 31, 2014, 2013 and 2012, were as follows:
			2014			2013			2012
Beginning balance		$	23,000		$	29,000		$	23,000
Warranty provisions			63,000			69,000			57,000
Warranty claims			(67,000	)		(75,000	)		(51,000	)
Ending balance		$	19,000		$	23,000		$	29,000
Advertising Costs
The Company follows the policy of charging production costs of advertising to expense as incurred.  Advertising expense was $127,000, $119,000 and $103,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
Stock-Based Compensation
The Company has various types of stock-based compensation plans.  These plans are administered by the Compensation Committee of the Board of Directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.  Refer to Notes 8 and 9 for additional information related to these stock-based compensation plans.
The following amounts have been recognized as stock-based compensation expense in the Consolidated Statements of Operations:
		2014			2013			2012
Stock-based compensation included in:
Cost of goods sold		$	282,000		$	196,000		$	94,000
Research and development			493,000			373,000			389,000
Clinical and regulatory			363,000			322,000			313,000
Sales and marketing			901,000			858,000			941,000
General and administrative			1,843,000			1,594,000			1,246,000
		$	3,882,000		$	3,343,000		$	2,983,000
The Company uses the Black-Scholes option-pricing model to estimate fair value of stock-based awards with the following weighted average assumptions:
		2014			2013			2012
Stock Options:
Expected life (years)									6.5
Expected volatility									48	%
Dividend yield									0	%
Risk-free interest rate									1.21	%
Employee Stock Purchase Plan:
Expected life (years)			2			2			2
Expected volatility			27	%		29	%		32	%
Dividend yield			0	%		0	%		0	%
Risk-free interest rate			0.44	%		0.32	%		0.28	%
Restricted stock awards fair value is calculated as the market price on the date of grant for the years ended December 31, 2014, 2013 and 2012 and the fair value is amortized on a straight-line basis over the requisite service period of four or nine years for employee awards and one year for board of director awards.  The weighted average fair value of restricted stock awards granted during 2014, 2013 and 2012 was $24.24, $16.31 and $11.10, respectively.
The weighted average fair value of stock options granted with an exercise price equal to the deemed stock price on the date of grant during 2012 was $5.41.  There were no stock option grants during 2014 and 2013.
The Company calculates expected volatility for stock options and awards using historical volatility over a period most closely associated with the expected life of the stock option or award.  The Company uses a 10% forfeiture rate for key employees and a 15% forfeiture rate for non-key employees for stock options and awards.  The Company calculates expected volatility for employee stock purchase plan shares using historical volatility over a two-year period.  A two-year period is used to coincide with the maximum two-year offering period under the employee stock purchase plan.  The risk-free rates for the expected terms of the stock options and awards and the employee stock purchase plan is based on the U.S. Treasury yield curve in effect at the time of grant.
Income Taxes
Income taxes are accounted for under the liability method.  Deferred income taxes are provided for temporary differences between the financial reporting and the tax bases of assets and liabilities.  Deferred tax assets are reduced by a valuation allowance to the extent that realization of the related deferred tax asset is not assured.  If the Company determines in the future that it is more likely than not that the Company will realize all or a portion of the deferred tax assets, the Company will adjust the valuation allowance in the period the determination is made (see Note 7).
When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained.  The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.  Tax positions taken are not offset or aggregated with other positions.  Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.  The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
The Company has recorded ASC 740, Income Taxes, reserves of $1,262,000 and $1,268,000 at December 31, 2014 and 2013.  The impact of tax related interest and penalties is recorded as a component of income tax expense.  At December 31, 2014, the Company has recorded $-0- for the payment of tax related interest and there were no tax penalties or interest recognized in the consolidated statements of earnings.
Net Earnings Per Common Share
In accordance with ASC 260, Earnings Per Share, basic net earnings per common share is computed by dividing net earnings by the weighted average common shares outstanding during the periods presented.  Diluted net earnings per common share is computed by dividing net earnings by the weighted average common and potential dilutive common shares outstanding computed in accordance with the treasury stock method.
The number of shares used in earnings per share computations is as follows for the years ended December 31:
		2014			2013			2012
Weighted average common shares outstanding— basic			16,891,643			16,412,322			16,003,932
Effect of dilutive securities			818,919			612,768			451,797
Weighted average common shares outstanding— diluted			17,710,562			17,025,090			16,455,729
The effect of dilutive securities in the above table excludes -0-, -0- and 270,000 of options for which the exercise price was higher than the average market price for the years ended December 31, 2014, 2013 and 2012, respectively.
Goodwill and Other Intangible Assets
Goodwill is reviewed for impairment annually on December 31st or more frequently if changes in circumstances or the occurrence of events suggest impairment exists using a two-step process.  In step 0, the Company can elect to perform an optional quantitative analysis and based on the results, skip the remaining two steps.  Consistent with prior years, in the current year the Company chose to skip step 0 and perform a quantitative analysis in Step 1.  In step 1, the fair value of each reporting unit is compared to its carrying value, including goodwill.  If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized.  If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would then complete step 2 in order to measure the impairment loss.  In step 2, the Company would calculate the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit.  If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss, in the period identified, equal to the difference.  The Company has concluded that no impairment of goodwill existed as of December 31, 2014.
Other intangible assets consist of purchased technology, trademark/tradename, developed technology, customer relationships and purchased licenses.  The Company reviewed intangible assets for impairment as changes in circumstances or the occurrence of events suggested the remaining value was not recoverable.
Amortization on the intangibles is provided on a straight-line basis over the estimated useful lives of the assets as follows:
Trademark/tradename	10 to 11 years
Purchased and developed technology	9 to 11 years
Customer relationships	9 years
Licenses	5 to 10 years
Leases and Deferred Rent
On December 1, 2014, the Company closed on the purchase of its primary manufacturing facility, a 79,000 square-foot building. This building was leased prior to the purchase.
On November 30, 2012, the Company closed on the purchase of an office building located next to the building which previously housed the Company’s principal executive offices.  The Company occupies approximately 50,000 square feet of the building and leases the remaining 26,000 square feet of the building to third-party tenants.
In addition, during the year ended December 31, 2014, the Company also leased additional warehouse and manufacturing space.  Leases are accounted for under the provisions of ASC 840, Leases, which requires that leases be evaluated and classified as operating or capital leases for financial reporting purposes.  As of December 31, 2014, all of the Company’s leases were accounted for as operating leases.  For leases that contain rent escalations, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents paid and the straight-line rent as a deferred rent.  For any lease incentives the Company receives for items such as leasehold improvements, the Company records a deferred credit for the amount of the lease incentive and amortizes it over the lease term, which may or may not equal the amortization period of the leasehold improvements in accordance with ASC 840-20.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	3. Goodwill and Other Intangible Assets
	The Company acquired trademark/tradename, developed technology and customer relationships most recently from the following (see Note 15):
		·	Accumed Systems, Inc. (Accumed) in June 2012,
		·	St. Jude Medical in August 2012, and
		·	Shepherd Scientific, Inc. (Shepherd Scientific) in December 2012
	The Company is amortizing these intangibles over their useful lives of 9 to 11 years.  The goodwill acquired in the same transactions will not be amortized.  In January 2012, the Company acquired the rights, patents and intellectual property relating to a two-lumen catheter for distal protection and material extraction used in the Company’s Pronto catheters (see Note 15).  In September 2013, the Company entered into a services agreement with Northeast Scientific, Inc. to obtain FDA approval for reprocessing another medical device (see Note 15).  Amortization expense was $1,642,000, $1,572,000 and $1,393,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
	Balances of acquired intangible assets as of December 31, 2014 were as follows:
			Carrying Amount			Accumulated			Net
						Amortization
	Amortizing intangibles:
	Purchased and developed technology		$	8,140,000		$	3,216,000		$	4,924,000
	Purchased licenses			5,050,000			1,515,000			3,535,000
	Trademark / tradename			2,210,000			806,000			1,404,000
	Customer relationships			640,000			204,000			436,000
	Foreign currency translation adjustments			(190,000	)		(55,000	)		(135,000	)
			$	15,850,000		$	5,686,000		$	10,164,000
	Balances of acquired intangible assets as of December 31, 2013 were as follows:
			Carrying Amount			Accumulated			Net
						Amortization
	Amortizing intangibles:
	Purchased and developed technology		$	8,140,000		$	2,360,000		$	5,780,000
	Purchased licenses			5,050,000			1,010,000			4,040,000
	Trademark / tradename			2,210,000			592,000			1,618,000
	Customer relationships			640,000			133,000			507,000
	Foreign currency translation adjustments			16,000			18,000			(2,000	)
			$	16,056,000		$	4,113,000		$	11,943,000
	Based on the intangibles assets as of December 31, 2014, future amortization expense will be as follows:
	2015		$	1,824,000
	2016			1,817,000
	2017			1,644,000
	2018			1,644,000
	2019			1,352,000
	Thereafter			1,883,000
			$	10,164,000
	The following table provides a summary of additions and disposals of goodwill for each reporting period:
	Balance at December 31, 2012		$	10,387,000
	Acquisition of Disposable Vein Hook			59,000
	Foreign currency translation adjustments			86,000
	Balance at December 31, 2013		$	10,532,000
	Foreign currency translation adjustments			(273,000	)
	Balance at December 31, 2014		$	10,259,000

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	4. Property, Plant and Equipment
	Property, plant and equipment consist of the following at December 31:
		2014			2013
	Plant and equipment:
	Manufacturing equipment	$	13,198,000		$	12,019,000
	Buildings		9,930,000			6,407,000
	Office and computer equipment		3,647,000			2,798,000
	Research and development equipment		3,404,000			2,567,000
	Leasehold improvements		2,526,000			2,489,000
	Furniture and fixtures		1,146,000			1,039,000
	Building improvements		790,000			665,000
	Construction-in-process		2,212,000			658,000
			36,853,000			28,642,000
	Less accumulated depreciation and amortization		(16,389,000	)		(14,055,000	)
	Net plant and equipment		20,464,000			14,587,000
	Land		5,201,000			1,600,000
	Net property, plant and equipment	$	25,665,000		$	16,187,000

Lines_of_Credit

Lines of Credit	12 Months Ended
	Dec. 31, 2014
Lines of Credit [Abstract]
Lines of Credit	5. Lines of Credit
	The Company had a secured asset-based revolving credit agreement with U.S. Bank National Association dated December 21, 2009 (as amended on December 6, 2012; December 20, 2011 and December 20, 2010).  The revolving credit agreement was a one-year, $10,000,000 facility with availability based primarily on eligible customer receivables, inventory and property and equipment.
	The revolving credit agreement expired on December 31, 2013 and has not been renewed.

Leases

Leases	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Leases	6. Leases
	The Company leases one building in Minnesota totaling approximately 26,000 square-feet, and leased its 79,000 square foot primary manufacturing facility through November 30, 2014, under operating leases.  The lease continues to remain in effect through September 2015 with an option to renew.  The Company leases one building in Ireland totaling approximately 1,150 square feet.  This lease is scheduled to expire in July 2015; however it does contain extension provisions.  Rent expense related to the operating leases was approximately $1,010,000, $1,350,000 and $1,273,000 for the years ended December 31, 2014, 2013, and 2012, respectively.
	Future minimum lease commitments under the operating leases as of December 31, 2014 will be as follows:
	2015	$	104,000
		$	104,000

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	7. Income Taxes
	At December 31, 2014, the Company had recorded the following components of deferred taxes with a finite life:
		2014			Expiration Date
	Federal and Minnesota research and development tax credit carryforwards	$	2,681,000		Beginning in 2015
	The Company has recorded an allowance of approximately $1,173,000 relating to those research and development tax credit carryforwards expected to expire prior to utilization.
	The Company is subject to income tax in numerous jurisdictions and at various rates and the use of estimates is required in determining the provision for income taxes.  For the year ended December 31, 2014, the Company recorded tax expense of $7,178,000 on earnings before tax of $19,912,000 resulting in an effective income tax rate of 36%.  For the year ended December 31, 2014, income before taxes relating to U.S. operations was $19,488,000, while income from foreign operations was $424,000.  For the year ended December 31, 2013, the Company recorded tax expense of $4,941,000 on earnings before tax of $16,083,000 resulting in an effective income tax rate of 31%.  For the year ended December 31, 2013, income before taxes relating to U.S. operations was $16,080,000, while loss from foreign operations was $108,000.  For the year ended December 31, 2012, income before taxes relating to U.S. operations was $15,594,000, while income from foreign operations was $298,000.
	The Company is subject to income tax examinations in the U.S. Federal jurisdiction, as well as in the Republic of Ireland and various state jurisdictions.  U.S. Federal and state tax years that remain open to examination at December 31, 2014 are 2011 through 2014.
	A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows:
	Balance at December 31, 2012	$	1,074,000
	Increases as a result of tax positions taken during a prior period		–
	Increases as a result of tax positions taken during the current period		223,000
	Reductions as a result of lapse of the applicable statute of limitations		(29,000	)
	Decreases relating to settlements with taxing authorities		–
	Balance at December 31, 2013	$	1,268,000
	Increases as a result of tax positions taken during a prior period		87,000
	Increases as a result of tax positions taken during the current period		97,000
	Reductions as a result of lapse of the applicable statute of limitations		(32,000	)
	Decreases as a result of state credits expected to expire unutilized		(158,000	)
	Balance at December 31, 2014	$	1,262,000
	A significant portion of the total of $1,262,000 relates to unrecognized tax benefits related to research and development credit carryforwards.  Therefore, $916,000 has been reflected as a reduction of the related research and development credit carryforward deferred tax asset.
	The components of the Company’s deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:
		2014				2013
	Deferred tax assets:
	Research and development (R&D) credit carryforwards	$	2,681,000			$	4,766,000
	Stock-based compensation		2,322,000				1,151,000
	Federal and state AMT credits		993,000				985,000
	Accrued compensation		636,000				578,000
	Inventory reserve		522,000				609,000
	Net operating loss carryforwards		471,000				–
	Depreciation and amortization		158,000				624,000
	Deferred revenue		154,000				229,000
	Foreign operations net operating loss carryforwards and timing differences		53,000				96,000
	Legal settlement		–				196,000
	Other		104,000				115,000
	Gross deferred tax assets		8,094,000				9,349,000
	Deferred tax liability relating to amortization		(803,000	)			(584,000	)
	Net deferred taxes assets before reserve for uncertain tax positions and valuation allowances		7,291,000				8,765,000
	Reserve for uncertain tax positions		(346,000	)			(882,000	)
	Less valuation allowances		(1,173,000	)			(144,000	)
	Net deferred tax assets	$	5,772,000			$	7,739,000
			2014				2013
	Deferred taxes recorded on the balance sheet:
	Deferred tax assets – current	$	3,681,000			$	6,000,000
	Deferred tax assets – long-term		2,894,000				1,739,000
	Deferred tax assets		6,575,000				7,739,000
	Deferred tax liabilities – long-term		803,000				–
	Net deferred tax assets	$	5,772,000			$	7,739,000
	The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable earnings.  At December 31, 2014, 2013 and 2012, the valuation allowance was $1,173,000, $144,000 and $1,434,000, respectively.  The increase (decrease) in the valuation allowance was $1,029,000, ($1,290,000) and ($683,000) for the years ended December 31, 2014, 2013 and 2012, respectively.  For the year ended December 31, 2014, based upon the Company’s assessment of all available evidence, including estimates of future profitability, the Company’s overall prospects of future business and the apportionment of the Company’s income to the State of Minnesota based on current apportionment methods, the Company determined that it is more likely than not that the Company will not be able to realize all remaining deferred tax assets relating to the Minnesota research and development credits and the Minnesota net operating loss carryforwards prior to their expirations.  As a result, the Company recorded additional income tax expense of $867,000 during the third quarter ended September 30, 2014 as a discrete adjustment to the valuation allowance for its deferred tax assets.  The Company continues to assess the potential realization of deferred tax assets on a quarterly basis.  If the Company’s actual results and updated projections vary significantly from the projections used as a basis for this determination, the Company may need to increase or decrease the valuation allowance against the gross deferred tax assets.  The Company does not anticipate the total unrecognized tax benefits will change significantly prior to December 31, 2015.  The Company will adjust earnings for the deferred tax in the period in which the determination is made.
	For the years ended December 31, 2014, 2013 and 2012, the Company recorded stock option and employee stock purchase plan tax benefits against “additional paid-in capital” and reduced taxes payable by a corresponding amount of $1,823,000, $2,084,000 and $1,135,000, respectively.
	Reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		2014				2013			2012
	Tax at federal statutory rate		35	%			34	%		34	%
	State income taxes, net of federal benefit		2.8				4.4			6.2
	Permanent differences		(1.3	)			(0.8	)		1.9
	Change in valuation reserve		4				0.2			0.2
	R&D credits generated		(2.4	)			(4.2	)		(1.1	)
	Reserve for uncertain tax positions		(1.8	)			0.9			0.1
	Foreign operations tax rate difference		(0.8	)			(0.5	)		(0.7	)
	Disallowed federal R&D credits at 12.31.12		–				(1.9	)		–
	Other adjustments		0.5				(1.0	)		(3.0	)
	Effective income tax rate		36	%			31.1	%		37.6	%
		2014				2013			2012
	Current taxes		29.6	%			26.8	%		12.8	%
	Deferred taxes		9.9				6.6			26.1
Benefit from foreign operation tax rates		(0.8	)			(0.5	)		(0.7	)
Benefit from domestic manufacturers deduction		(2.7	)			(1.8	)		(0.6	)
Effective income tax rate		36	%			31.1	%		37.6	%

Stock_Options_and_Restricted_S

Stock Options and Restricted Shares	12 Months Ended
	Dec. 31, 2014
Stock Options and Restricted Shares [Abstract]
Stock Options and Restricted Shares	8. Stock Options and Restricted Shares
	Stock Option and Stock Award Plan
	The Company has a stock option and stock award plan (the Stock Option Plan) which provides for the granting of stock options, restricted shares and stock appreciation rights to employees, directors, and consultants.  Incentive stock options may be granted only to employees of the Company.  Options which do not qualify as incentive stock options and awards of restricted shares may be granted to both employees and to non-employee directors and consultants.  As of December 31, 2014, the Company had reserved 5,500,000 shares of common stock under the Stock Option Plan.  Under the Stock Option Plan, stock options must be granted at an exercise price not less than the fair market value of the Company’s common stock on the grant date.  Vesting requirements of all awards under this plan are time based and vary by individual grant.  The options expire on the date determined by the Board of Directors but may not extend more than 10 years from the grant date.  The incentive stock options generally become exercisable over a four-year period and the nonqualified stock options generally become exercisable over a one-year period.  Vested and unexercised options are canceled three-months after termination, and unvested awards are canceled on the date of termination of employment and become available under the Stock Option Plan for future grants.
	Prior to 2013 the Company granted annual stock options to its directors under the Stock Option Plan.  The ten-year options issued to the Company’s directors vested over a one-year period based on the continuation of service as a director of the Company.  The Company used a 0% forfeiture rate for all director options granted.
	In January 2012, the Company granted stock options to the chief executive officer under the Stock Option Plan.  The ten-year options issued to the Company’s chief executive officer vest over five successive one-year periods based on the continuation of service with the Company and contain a $1 per share escalation in the exercise price each year.  The Company used a 0% forfeiture rate for this option grant.
	Option activity is summarized as follows:
			Shares				Plan Options				Exercise				Weighted Average Exercise				Aggregate
			Available				Outstanding				Price				Price				Intrinsic
			for Grant																Value
			(exclusive of restricted
			shares issued)
	Balance at December 31, 2011			4,327,000				801,000			$	0.78–$11.72			$	7.38
	Shares reserved			(1,900,000	)			–				–				–
	Granted			(500,000	)			500,000				11.03– 15.03				12.89
	Exercised			–				(158,000	)			0.84– 10.28				3.1
	Forfeited			–				–				–				–
	Expired			–				–				–				–
	Balance at December 31, 2012			1,927,000				1,143,000			$	0.78–$15.03			$	10.38
	Shares reserved			500,000				–				–				–
	Granted			–				–				–				–
	Exercised			–				(354,000	)			0.78– 11.72				7.86
	Forfeited			–				–				–				–
	Expired			1,000				(1,000	)			0.84– 5.74				5.38
	Balance at December 31, 2013			2,428,000				788,000			$	6.36–$15.03			$	11.52
	Shares reserved			–				–				–				–
	Granted			–				–				–				–
	Exercised			–				(102,000	)			6.74– 10.89				9.52
	Forfeited			–				–				–				–
	Expired			4,000				(4,000	)			6.74– 10.10				8.61
	Balance at December 31, 2014			2,432,000				682,000			$	6.36–$15.03			$	11.84			$	10,440,000
	Exercisable at December 31, 2014							410,000							$	10.4			$	6,870,000
	The number of common shares available for the grant of future stock awards is limited to 859,000 common shares.  The shares available for grant number disclosed in the table above includes 1,573,000 common shares issued in the form of restricted shares.
	The weighted average remaining contractual term of options exercisable at December 31, 2014, was 5.6 years. The total intrinsic value of options exercised during fiscal 2014, 2013 and 2012, was $1,595,000, $3,057,000 and $1,464,000, respectively.
	The following table summarizes information about stock options outstanding at December 31, 2014:
					Options Outstanding												Options Exercisable
	Range of				Outstanding				Weighted				Weighted				Exercisable				Weighted
	Exercise Prices				as of				Average				Average				as of				Average
					December 31,				Remaining Contractual Life				Exercise Price				December 31,				Exercise Price
					2014												2014
	$	6.36–$ 7.88				70,000				3.2			$	6.81				70,000			$	6.81
		7.89– 10.98				82,000				3.3				9.74				82,000				9.74
		10.99– 11.72				170,000				6.9				11.34				168,000				11.34
		11.73– 12.03				90,000				7.1				12.03				90,000				12.03
		12.04– 13.03				90,000				7.1				13.03				–				–
		13.04– 15.03				180,000				7.1				14.53				–				–
						682,000				6.2			$	11.84				410,000			$	10.4
	As of December 31, 2014, there was $863,000 of total unrecognized compensation costs related to the outstanding stock options, which is expected to be recognized over a weighted average period of 1.1 years.
	The holder of a restricted share award is generally entitled at all times on and after the date of issuance of the restricted shares to exercise the rights of a shareholder of the Company, including the right to vote the shares and the right to receive dividends on the shares.  These shareholders do not have the ability to sell, transfer or otherwise encumber the restricted share awards until they fully vest.  During 2014, 2013 and 2012, the Company granted restricted shares to directors and employees under the Stock Option Plan.  The restricted shares granted to employees of the Company vest over a four-year or nine-year period based on the continuation of employment.  The restricted shares granted to the Company’s director’s vest over a one-year period based on the continuation of service as a director.
	Restricted share activity is summarized as follows:
			Shares				Weighted Average
			Outstanding				Grant Date Fair
							Value
	Balance at December 31, 2011			567,000			$	9.43
	Granted			245,000				11.1
	Vested			(167,000	)			8.12
	Forfeited			(32,000	)			10.67
	Balance at December 31, 2012			613,000			$	10.39
	Granted			199,000				16.31
	Vested			(208,000	)			9.96
	Forfeited			(16,000	)			11.22
	Balance at December 31, 2013			588,000			$	12.52
	Granted			175,000				24.24
	Vested			(247,000	)			11
	Forfeited			(9,000	)			17.23
Balance at December 31, 2014			507,000			$	17.24
As of December 31, 2014, there was $2,576,000 of total unrecognized compensation costs related to the outstanding restricted shares, which is expected to be recognized over a weighted average period of 1.47 years.
The Company estimates the forfeiture rate for restricted stock using 0% for directors, 10% for key employees and 15% for non-key employees.

Employee_Stock_Purchase_Plan

Employee Stock Purchase Plan	12 Months Ended
	Dec. 31, 2014
Employee Stock Purchase Plan [Abstract]
Employee Stock Purchase Plan	9. Employee Stock Purchase Plan
	The Company has an Employee Stock Purchase Plan (the Purchase Plan) under which 2,700,000 shares of common stock have been reserved for issuance.  Eligible employees may contribute 1% to 10% of their compensation to purchase shares of the Company’s common stock at a discount of 15% of the market value at certain plan-defined dates, up to a maximum of 2,000 shares per purchasing period.  The Purchase Plan terminates in July 2020. In fiscal 2014, 2013 and 2012, 103,500 shares, 124,100 shares, and 114,100 shares, respectively, were issued under the Purchase Plan.  At December 31, 2014, 862,000 shares were available for issuance under the Purchase Plan.
	As of December 31, 2014, there was $381,000 of total unrecognized compensation costs related to the Purchase Plan, which is expected to be recognized over a weighted average period of 0.78 years.

Employee_Retirement_Savings_Pl

Employee Retirement Savings Plan	12 Months Ended
	Dec. 31, 2014
Employee Retirement Savings Plan [Abstract]
Employee Retirement Savings Plan	10. Employee Retirement Savings Plan
	The Company has an employee 401(k) retirement savings plan (the Plan).  The Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program.  All employees over the age of 21 are eligible to participate in the Plan beginning with the first quarterly open enrollment date following start of employment.  The Plan allows eligible employees to contribute up to 50% of their annual compensation, subject to a maximum limit determined by the Internal Revenue Service, with the Company contributing an amount equal to 25% of the first 10% contributed to the Plan.  The Company recorded an expense of $408,000, $243,000 and $204,000 for contributions to the Plan for the years ended December 31, 2014, 2013, and 2012, respectively.

Concentrations_of_Credit_and_O

Concentrations of Credit and Other Risks	12 Months Ended
	Dec. 31, 2014
Concentrations of Credit and Other Risks [Abstract]
Concentrations of Credit and Other Risks	11. Concentrations of Credit and Other Risks
	In the United States the Company sells its products directly to hospitals and clinics.  In all international markets, the Company sells its products to distributors who, in turn, sell to hospitals and clinics.  Loss, termination, or ineffectiveness of distributors to effectively promote the Company’s product could have a material adverse effect on the Company’s financial condition and results of operations.
	No customer represented more than 10% of total revenue for any year ended December 31, 2014, 2013 and 2012.
	The Company performs credit evaluations of its customers and does not require collateral to extend credit to an account.  No customer represented more than 10% of gross accounts receivable at December 31, 2014 and 2013. There have been no material losses on customer receivables.
	Product revenue by geographic destination as a percentage of total product revenues were as follows for the years ended December 31:
		2014			2013			2012
	Domestic		82	%		85	%		84	%
	Foreign		18			15			16

Related_Party_Activity

Related Party Activity	12 Months Ended
	Dec. 31, 2014
Related Party Activity [Abstract]
Related Party Activity	12. Related Party Activity
	During the years ended December 31, 2014, 2013 and 2012, the Company sold $311,000, $361,000 and $451,000, respectively, of product to a company of which a board member of the Company is an officer.  As of December 31, 2014 and 2013, the Company had an accounts receivable balance due of $35,000 and $14,000, respectively, from this related party.  In addition, the Company purchases product from this related party and during the years ended December 31, 2014, 2013 and 2012 the Company purchased $18,000, $10,000 and $10,000, respectively, of product from this related party.  As of both December 31, 2014 and 2013, the Company had an accounts payable balance due of $-0- to this related party.

Dependence_on_Key_Suppliers

Dependence on Key Suppliers	12 Months Ended
	Dec. 31, 2014
Dependence on Key Suppliers [Abstract]
Dependence on Key Suppliers	13. Dependence on Key Suppliers
	King Pharmaceuticals
	The Company purchases certain key components from single-source suppliers.  Any significant component delay or interruption could require the Company to qualify new sources of supply, if available, and could have a material adverse effect on the Company’s financial condition and results of operations.  The Company purchases its requirements for thrombin (a component in the Hemostat products) under a Thrombin-JMI Supply Agreement entered into with King Pharmaceuticals, Inc. (King) on January 9, 2007.  Under the terms of the Thrombin-JMI Supply Agreement, King agrees to manufacture and supply thrombin to the Company on a non-exclusive basis.  The Thrombin-JMI Supply Agreement does not contain any minimum purchase requirements.
	King agrees to supply the Company with such quantity of thrombin as the Company may order at a fixed price throughout the term of the Thrombin-JMI Supply Agreement as adjusted for inflation, variations in potency and other factors.  The Thrombin-JMI Supply Agreement has an initial term of 10 years, followed by successive automatic one-year extensions, subject to termination by the parties under certain circumstances, including: (i) termination by King without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to the Company, and (ii) termination by the Company without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to King provided that the Device Supply Agreement, which the Company also entered into with King on January 9, 2007, has expired on its terms or the parties have agreed to terminate it.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies
	All legal cost related to litigation are charged to operations as incurred, except settlements which are expensed when a claim is probable and estimable.
	Boston Scientific Corporate Litigation
	On May 16, 2013, the Company filed a patent infringement complaint in the United States District Court for the District of Minnesota against Boston Scientific Corporation (Boston Scientific).  The complaint alleged that Boston Scientific infringed three of the Company’s patents concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla™ guide extension catheter.  On July 11, 2013, Boston Scientific filed its answer and counterclaim, alleging the Company’s patents are invalid, that the Guidezilla catheter does not infringe, and that the Company’s manufacture and sale of its GuideLiner catheter violates a U.S. patent owned by Boston Scientific that expired in June 2013.  On July 30, 2014, the Company agreed with Boston Scientific to settle the patent lawsuit and counterclaim.  As part of the settlement agreement, all litigation relating to guide extension was dismissed and the Company will receive an ongoing royalty from Boston Scientific in exchange for a license of the Company’s patents.  The terms of the settlement agreement are confidential.
	Governmental Proceedings
	On June 28, 2011, the Company received a subpoena from the U.S. Attorney’s Office for the Western District of Texas under the Health Insurance Portability & Accountability Act of 1996 (HIPAA) requesting the production of documents related to Vari-Lase products, and in particular the use of the Vari-Lase Short Kit for the treatment of perforator veins.  Subsequently, the Company learned that the U.S. Attorney’s Office also had commenced a criminal investigation of the same matter.  The Vari-Lase Short Kit was sold under a 510(k) clearance for the treatment of incompetence and reflux of superficial veins in the lower extremity from 2007 until it was voluntarily withdrawn from the market in July 2014 with total U.S. sales of approximately $534,000 (0.1% of the Company’s total U.S. sales for such period) and has not been the subject of any reported serious adverse clinical event.  On August 14, 2012, the United States District Court for the Western District of Texas unsealed a qui tam complaint that had been filed on November 19, 2010 by Desalle Bui, a former sales employee of the Company, which was the basis for the U.S. Attorney’s civil investigation, to which the federal government, after three extensions of time, elected to intervene.  The complaint contained allegations of off-label promotion of Vari-Lase products for the treatment of perforator veins, re-use of single-use Vari-Lase products and kickbacks to physicians, resulting in alleged damages to the government of approximately $20 million.  An amended complaint limited to allegations of off-label promotion of the Vari-Lase Short Kit resulting in an unspecified amount of damages and penalties was filed by the U.S. Attorney’s Office in December 2012.  On January 22, 2014, the Company agreed with the U.S. Attorney’s Office to settle the civil lawsuit, and the settlement agreement was executed on July 28, 2014.  Under the terms of the settlement agreement, the Company made a payment of $520,000, the Company made no admission of fault or liability, and the U.S. Attorney’s Office dismissed the civil lawsuit with prejudice and released all civil claims brought against the Company in the civil lawsuit.  Settlement of the civil lawsuit had no effect upon the criminal investigation.
	On November 11, 2014, a criminal indictment was issued in the United States District Court for the Western District of Texas related to the Vari-Lase Short Kit investigation.  The indictment alleges that the Company and its Chief Executive Officer introduced adulterated and misbranded medical devices into interstate commerce and conspired to introduce adulterated and misbranded medical devices into interstate commerce through the alleged off-label promotion of the Vari-Lase Short Kit.  The Company believes the allegations are false and intends to contest them vigorously.  Defending the Company against the indictment will entail costs that are expected to be material and will require significant attention from the Company’s management.  If the Company were to be convicted of the crimes alleged in the indictment, remedies could include fines, penalties, forfeitures and compliance conditions.  Given the early stage of this proceeding, the Company cannot estimate the amount or range of loss if the Company were to be convicted; however, it would likely be material.  If the Company were to be convicted of a crime related to the delivery of an item or service under Title XVIII of the Social Security Act, or a felony related to health care fraud, it would become automatically excluded by the Department of Health and Human Services (“HHS”) from participation in U.S. government health care programs, including Medicare and Medicaid.  If the Company were to be convicted of a misdemeanor related to health care fraud, it could be excluded by HHS from participation in U.S. government health care programs, including Medicare and Medicaid.  Exclusion from participation in U.S. government health care programs would substantially adversely affect the Company’s ability to continue to conduct its business.  Conviction of the Company’s chief executive officer of a crime under statutes related to misbranding and health care fraud could require the termination of his employment with the Company.
	From time to time, the Company is involved in additional legal proceedings arising in the normal course of business.  As of the date of this report the Company is not a party to any legal proceeding not described in this Note in which an adverse outcome would reasonably be expected to have a material adverse effect on the Company’s results of operations or financial condition.
	King Agreements
	On January 9, 2007, the Company entered into a License Agreement and a Device Supply Agreement with King (see Note 13).  King was acquired by Pfizer, Inc. on February 28, 2011.  Under the License Agreement, the Company licensed the exclusive rights to the Company’s products Thrombi-Pad, Thrombi-Gel and Thrombi-Paste to King in exchange for a one-time license fee.  Under the Device Supply Agreement, the Company agreed to manufacture the licensed products for sale to King in exchange for an initial payment.  The unamortized license fee was $406,000, $610,000 and $815,000 at December 31, 2014, 2013 and 2012, respectively.  Amortization of the deferred revenue will be $204,000 per year for the remainder of the 10-year license period.  The amortization of license fee was $204,000, $205,000, and $204,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
	Nicolai, GmbH Agreement
	Effective April 1, 2008, the Company entered into a five-year distribution agreement with Nicolai GmbH.  In connection with this distribution agreement, the Company received 500,000 Euros from Nicolai GmbH, which was deferred and was being recognized ratably over the five-year term of the distribution agreement.  The agreement included provisions requiring the Company to pay Nicolai GmbH specific amounts if the Company terminated the distribution agreement prior to the end of the five-year term.  The Company did not terminate the distribution agreement prior to the termination date.  The unamortized license fee was $-0-, $-0- and $36,000 at December 31, 2014, 2013 and 2012, respectively.  The amortization of license fee was $-0-, $36,000 and $146,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
	On November 14, 2014, the Company’s Board of Directors approved a Common Stock Repurchase Plan (the “Repurchase Plan”), which provides the option to repurchase shares of the Company’s common stock with a maximum purchase price of $20,000,000 on the open market at market prices through December 31, 2015.  During the year ended December 31, 2014, the Company repurchased a total of 33,401 common shares at an average price of $24.52 under the plan.

Business_Combinations_and_Asse

Business Combinations and Asset Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations and Asset Acquisitions [Abstract]
Business Combinations and Asset Acquisitions	15. Business Combinations and Asset Acquisitions
	During the first quarter of fiscal year 2010, the Company adopted ASC 805, Business Combinations, related to business combinations.  This authoritative guidance establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interests in the acquiree and the goodwill acquired.  The underlying purchase method of accounting for acquisitions was retained, but the new guidance incorporates a number of changes.  These changes include the capitalization of purchased in-process research and development, expensing of acquisition related costs and the recognition of contingent purchase price consideration at fair value at the acquisition date.
	When the Company acquires another company or a group of assets, the purchase price is allocated, as applicable, among in-process research and development, other identifiable intangible assets, net tangible assets and the remainder, if any, is recognized as goodwill, as required by U.S. GAAP.  Goodwill represents the excess of the aggregate purchase price over the fair value of net assets of acquired businesses, which is not amortized in accordance with ASC 350, Intangibles-Goodwill and Other.  The values assigned to other identifiable intangible assets are based on valuations as determined by the Company or independent third party appraisers.  The techniques used by these appraisers include estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values utilizing an appropriate risk-adjusted rate of return (discount rate).  The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods.
	Shepherd Scientific, Inc.
	On December 21, 2012, the Company acquired the assets relating to the Teirstein Edge™ device organizer and AngioAssist™ docking station from Shepherd Scientific, Inc. (Shepherd Scientific).  Under the terms of the agreement, the Company agreed to pay Shepherd Scientific a total of $500,000, which was paid on December 21, 2012 at closing.  The Teirstein Edge assists in the organization of guidewires and catheters during interventional procedures, while the AngioAssist facilitates the introduction of guidewires into catheters and atherectomy burrs.
	The Company accounted for the transaction as a business combination in the fourth quarter of 2012.   In accordance with ASC 805, the purchase price was allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Purchased technology	$	170,000
	Inventory and equipment		70,000
	Other intangibles		50,000
	Goodwill		210,000
		$	500,000
	Amortizable Acquired Assets
	Purchased technology.  Purchased technology consists of $170,000 of developed technology acquired.  The technology was valued using the income method utilizing a discounted cash flow model.  The Company is amortizing the technology assets on a straight-line basis over their estimated useful life of nine years.
	Other intangibles.  Other intangibles consist of $30,000 representing trademarks and trade names relating to the Teirstein Edge and AngioAssist products and $20,000 representing customer relationships.  The customer relationships relate to the ability to sell existing and future services to existing customers of Shepherd Scientific.  The fair value of trademarks and trade names and customer relationships was estimated using the income method utilizing a discounted cash flow model. The Company is amortizing the trademark and trade name intangible assets on a straight-line basis over their estimated useful life of approximately ten years.  The customer relationship intangible assets are being amortized on a straight-line basis over nine years.
	The weighted average amortization period for total amortizable intangible assets acquired in connection with the acquisition of the Teirstein Edge and AngioAssist products is nine years.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired.  The establishment of goodwill was primarily due to the expected revenue growth that is attributable to increased market penetration from future customers.  All of the goodwill is expected to be deductible for income tax purposes.
	With the exception of sales to one customer, the Company was the sole U.S. distributor of Teirstein Edge and AngioAssist products prior to the acquisition.
	St. Jude Medical, Cardiology Division, Inc.
	On August 16, 2012, the Company acquired the assets related to the Venture wire control catheter from St. Jude Medical, Cardiology Division, Inc. (“St. Jude Medical”).  Under the terms of the agreement, the Company agreed to pay St. Jude Medical a total of $3,000,000, consisting of $2,250,000 paid in cash at August 16, 2012 and $750,000 paid in cash on April 17, 2013, upon the successful completion of the transfer of the manufacturing processes from St. Jude Medical to the Company.  The Venture wire control catheter is used as a deflectable tip catheter for steering a 0.014 inch guidewire via the arterial system to the coronary or peripheral vasculature.  This acquisition provides the Company with additional products that are sold directly into the Company’s existing customer base to generate incremental revenue.
	The Company accounted for the transaction as a business combination in the third quarter of 2012.   In accordance with ASC 805, the purchase price was allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Purchased technology	$	850,000
	Other intangibles		500,000
	Inventory and equipment		189,000
	Goodwill		1,461,000
		$	3,000,000
	Amortizable Acquired Assets
	Purchased technology.  Purchased technology consists of $850,000 of developed technology acquired.  The technology was valued using the income method utilizing a discounted cash flow model.  The Company started amortizing the technology assets on a straight-line basis over their estimated useful life of nine years once the Company started selling the products in the second quarter of 2013.
	Other intangibles.  Other intangibles consist of $220,000 representing trademarks and trade names relating to the Venture wire control catheter products and $280,000 representing customer relationships.  The customer relationships relate to the ability to sell existing and future products and services to existing customers of St. Jude Medical.  The fair value of trademarks and trade names and customer relationships has been estimated using the income method utilizing a discounted cash flow model.  The Company started amortizing the trademark and trade name intangible assets on a straight-line basis over their estimated useful life of approximately ten years once the Company started selling the products in the second quarter of 2013.  The customer relationship intangible assets are being amortized on a straight-line basis over nine years.
	The weighted average amortization period for total amortizable intangible assets acquired in connection with the acquisition of the Venture wire control catheter products is nine years.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired.  The establishment of goodwill was primarily due to the expected revenue growth associated with this new product for the Company and possibility of selling additional products to these new customers.  All of the goodwill is expected to be deductible for income tax purposes.
	The Company has recognized additional revenue of $3,448,000 and net earnings of approximately $2,197,000 relating to the sale of Venture wire control catheter through December 31, 2014.
	Accumed Systems, Inc.
	On June 11, 2012, the Company acquired the assets related to the Accumed wrist positioning splint business from Accumed Systems, Inc. (“Accumed”).  Under the terms of the agreement, the Company paid Accumed a total of $1,500,000 at closing and no additional payments are required to be made.  The Accumed wrist positioning splint product consists of a plastic molded brace that simplifies arterial access by holding the wrist and forearm in an appropriate, comfortable position.  This acquisition provides the Company with an additional product that is sold directly into the Company’s existing customer base to generate incremental revenue.
	The Company accounted for the transaction as a business combination in the second quarter of 2012.   In accordance with ASC 805, the purchase price was allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Purchased technology	$	740,000
	Other intangibles		190,000
	Inventory and equipment		8,000
	Goodwill		562,000
		$	1,500,000
	Amortizable Acquired Assets
	Purchased technology.  Purchased technology consists of $740,000 of developed technology acquired.  The technology was valued using the income method utilizing a discounted cash flow model.  The Company is amortizing the technology assets on a straight-line basis over their estimated useful life of nine years.
	Other intangibles.  Other intangibles consist of $100,000 representing trademarks and trade names relating to the Accumed wrist positioning splint products and $90,000 representing customer relationships.  The customer relationships relate to the ability to sell existing and future products and services to existing customers of Accumed.  The fair value of trademarks and trade names and customer relationships has been estimated using the income method utilizing a discounted cash flow model.  The Company is amortizing the trademark and trade name intangible assets on a straight-line basis over their estimated useful life of approximately ten years.  The customer relationship intangible assets are being amortized on a straight-line basis over nine years.
	The weighted average amortization period for total amortizable intangible assets acquired in connection with the acquisition of the Accumed wrist positioning splint products is nine years.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired.  The establishment of goodwill was primarily due to the expected revenue growth that is attributable to increased market penetration from future customers.  All of the goodwill is expected to be deductible for income tax purposes.
	The Company has recognized additional revenue of $2,497,000 and net earnings of approximately $1,247,000 relating to the sales of the Accumed wrist positioning splint products from June 11, 2012 through December 31, 2014.
	Dr. Pedro Silva and Affiliates
	On January 6, 2012, the Company entered into an agreement with Dr. Pedro Silva and his affiliates, whereby the Company paid $3,250,000 for the rights, patents and intellectual property relating to a two-lumen catheter for distal protection and material extraction used in the Company’s Pronto catheters.  Upon payment, the existing License Agreement between N.G.C. Medical S.p.A. and the Company has been deemed paid-in-full, and no future royalties will be owed on any sale of a Pronto catheter after December 31, 2011.
	The Company has accounted for the transaction as a non-business license acquisition in the first quarter of 2012.   In accordance with ASC 805, the purchase price was assigned to a license intangible asset equivalent to the cash amount paid on January 6, 2012, and no goodwill was recognized.  The Company is amortizing the license intangible on a straight-line basis over a period of ten years.
	Northeast Scientific
	On September 17, 2013, the Company entered into an eight-year reprocessing services agreement with Northeast Scientific, Inc. (NES), a FDA-registered reprocessor of medical devices, whereby the Company paid NES a non-refundable amount of $500,000 for the exclusive right to offer NES’ reprocessing services in the United States for a commercial medical device.  NES is pursuing FDA approval for its reprocessing services for the device.  If FDA approval is obtained, the Company is required to pay NES a non-refundable amount of $400,000.  The agreement has an annual minimum unit termination clause, allowing NES to terminate the agreement if the Company does not meet certain annual minimums following FDA approval.
	The Company has accounted for the transaction as a non-business asset acquisition in the third quarter of 2013.  In accordance with ASC 805, the purchase price of $900,000 was assigned to an intangible and no goodwill was recognized.  The Company recorded a $400,000 accrual in the third quarter of 2013 in addition to the $500,000 payment, and since FDA approval has not occurred, $400,000 remains in accruals at December 31, 2014.  The Company will begin amortizing the intangible asset on a per unit basis over the remaining term of the agreement once the Company begins to send units to NES to be reprocessed following FDA approval.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) [Abstract]
Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data)	16. Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data)
	2014	Fourth Quarter		Third Quarter		Second Quarter		First Quarter
	Net revenue:
	Product	$	33,449	$	31,766	$	30,606	$	29,845
	License, royalty & collaboration		137		163		71		62
	Total net revenue		33,586		31,929		30,677		29,907
	Selected costs and expenses:
	Costs of goods sold		11,542		10,291		10,283		9,583
	Operating earnings		5,312		5,213		5,031		4,371
	Net earnings		4,160		2,570		3,205		2,799
	Basic net earnings per share	$	0.25	$	0.15	$	0.19	$	0.17
	Diluted net earnings per share	$	0.23	$	0.15	$	0.18	$	0.16
	2013	Fourth Quarter		Third Quarter		Second Quarter		First Quarter
	Net revenue:
	Product	$	29,000	$	27,926	$	27,294	$	25,977
	License		72		83		59		87
	Total net revenue		29,072		28,009		27,353		26,064
	Selected costs and expenses:
	Costs of goods sold		9,724		9,197		8,538		8,697
	Operating earnings		4,731		4,020		4,442		2,904
	Net earnings		3,537		2,672		2,808		2,125
	Basic net earnings per share	$	0.21	$	0.16	$	0.17	$	0.13
	Diluted net earnings per share	$	0.2	$	0.16	$	0.17	$	0.13

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events
	In January 2015, the Company entered into a purchase agreement to acquire a manufacturing and office building of approximately 26,000 square feet located adjacent to the Company’s existing manufacturing facility.  The Company expects the purchase to close in the first quarter of 2015, subject to customary closing conditions.  The Company intends to occupy 17,500 square feet of the building, with an existing tenant expected to occupy the remaining 8,500 square feet.

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2014
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS [Abstract]
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	Vascular Solutions, Inc.
	SCHEDULE II
	VALUATION AND QUALIFYING ACCOUNTS
	YEARS ENDED DECEMBER 31, 2014, 2013 AND 2012
	Description	Balance at Beginning of Year		Additions Charged		Less Deductions			Balance at
				to Costs					End of
				and					Year
				Expenses
	YEAR ENDED DECEMBER 31, 2014:
	Sales return allowance	$	50,000	$	65,000	$	(35,000	)	$	80,000
	Allowance for doubtful accounts		150,000		185,000		(115,000	)		220,000
	Total	$	200,000	$	250,000	$	(150,000	)	$	300,000
	YEAR ENDED DECEMBER 31, 2013:
	Sales return allowance	$	55,000	$	20,000	$	(25,000	)	$	50,000
	Allowance for doubtful accounts		130,000		90,000		(70,000	)		150,000
	Total	$	185,000	$	110,000	$	(95,000	)	$	200,000
	YEAR ENDED DECEMBER 31, 2012:
	Sales return allowance	$	30,000	$	45,000	$	(20,000	)	$	55,000
	Allowance for doubtful accounts		120,000		75,000		(65,000	)		130,000
	Total	$	150,000	$	120,000	$	(85,000	)	$	185,000

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation
	The consolidated financial statements include the accounts of Vascular Solutions, Inc. and its wholly-owned subsidiary Vascular Solutions Zerusa Limited, after elimination of intercompany accounts and transactions.
Segment Reporting	Segment Reporting
	A business segment is a distinguishable component of an enterprise that is engaged in providing an individual product or service or a group of related products or services and that is subject to risks and returns that are different from those of other business segments.  The Company’s segments have similar economic characteristics and are similar in the nature of the products sold, type of customers, methods used to distribute the Company’s products and regulatory environment.  Management believes that the Company meets the criteria for aggregating its operating segments into a single reporting segment.
	The Company uses three product categories for reporting revenue.  The following table sets forth, for the periods indicated, net revenue by product category along with the percent change from the previous year:
			For Years Ended December 31,
			2014						2013						2012
			Net Revenue			Percent Change			Net Revenue			Percent Change			Net Revenue		Percent Change
	Catheter products		$	82,885,000			19	%	$	69,936,000			14	%	$	61,262,000		16	%
	Hemostat products			24,389,000			3	%		23,752,000			5	%		22,676,000		(2	%)
	Vein products			18,392,000			11	%		16,509,000			17	%		14,098,000		34	%
	Total product revenue			125,666,000			14	%		110,197,000			12	%		98,036,000		13	%
	License, royalty & collaboration			433,000			44	%		301,000			(14	%)		350,000		(90	%)
	Total Net Revenue		$	126,099,000			14	%	$	110,498,000			12	%	$	98,386,000		9	%
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions
	The functional currency of the company's foreign operations is the applicable local currency.  The functional currency is translated into U.S. dollars for balance sheet accounts using current exchange rates in effect as of the balance sheet date and for revenue and expense accounts using a weighted-average exchange rate during the fiscal year.  The translation adjustments are deferred as a component of other comprehensive income within the consolidated statements of comprehensive income and the consolidated statements of shareholders’ equity.  Gains or losses resulting from transactions denominated in foreign currencies are included in other income, net in the consolidated statements of earnings.
	The Company sells products to an international distributor in Germany at prices denominated in Euros.  As a result, the Company is exposed to foreign exchange movements during the time between the shipment of the product and payment.  The Company currently has terms of net 60 days with this distributor under the agreement providing for payment in Euros.
Comprehensive Earnings	Comprehensive Earnings
	The components of comprehensive earnings are net earnings and the effects of foreign currency translation adjustments.  The accumulated other comprehensive earnings for the foreign currency translation adjustment at December 31, 2014 and 2013 was ($725,000) and ($1,000), respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying amount for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximates fair value due to the immediate or short-term maturity of these financial instruments.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of deferred tax assets and liabilities, as well as other amounts in the financial statements and accompanying notes.  Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company classifies all highly liquid investments with initial maturities of three months at the date of purchase or less as cash equivalents.  Cash equivalents consist of cash and money market funds and are stated at cost, which approximates market value.  The Company deposits its cash in high quality financial institutions.  The balances, at times, may exceed federally insured limits.
Credit Risk and Allowance for Doubtful Accounts	Credit Risk and Allowance for Doubtful Accounts
	The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments.  This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay.  Accounts receivable over 60 days past due are considered past due.  The Company does not accrue interest on past due accounts receivable.  Receivables are written off only after all collection attempts have failed and are based on individual credit evaluation and the specific circumstances of the customer.  At December 31, 2014 and 2013, the allowance for doubtful accounts was $220,000 and $150,000, respectively.
	All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.  The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on its balance sheet.  At December 31, 2014 and 2013, the sales and return allowance was $80,000 and $50,000, respectively.
	Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $300,000 and $200,000 at December 31, 2014 and 2013, respectively.
Inventories	Inventories
	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.   Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following at December 31:
			2014			2013
	Raw materials		$	8,251,000		$	6,386,000
	Work-in-process			1,139,000			926,000
	Finished goods			6,518,000			6,690,000
			$	15,908,000		$	14,002,000
Property, Plant and Equipment	Property, Plant and Equipment
	Property, plant and equipment are stated at cost.  Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Manufacturing equipment	1 to 8 years
	Office and computer equipment	1 to 5 years
	Furniture and fixtures	3 to 8 years
	Leasehold improvements	Shorter of useful life or remaining term of the lease
	Research and development equipment	3 to 7 years
	Building improvements	1 to 30 years
	Building	30 years
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	The Company will record impairment losses on long-lived assets when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount.  The amount of impairment loss recorded will be measured as the amount by which the carrying value of the assets exceeds the fair value of the assets.  To date, the Company has determined that no impairment of long-lived assets exists.
Revenue Recognition	Revenue Recognition
	In the United States, the Company sells its products and services directly to hospitals and clinics.  Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers.   The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.
	In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics.  The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor. The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor.  Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order and is reported on a gross basis.  Allowances are provided for estimated returns and costs at the time of shipment.  Sales and use taxes are reported on a net basis, excluding them from revenue.
	The Company’s revenues from license agreements and research collaborations are recognized when earned (see Note 14).  In accordance with ASC 605, for revenues which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller.  Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit.  Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC 605.
	The Company currently has a license agreement with King Pharmaceuticals, Inc. (King), now a subsidiary of Pfizer, Inc., under which the Company licensed the exclusive rights of Thrombi-Pad®, Thrombi-Gel® and Thrombi-Paste TM products to King in exchange for a license fee.  The Company is amortizing the license fees on a straight-line basis over the projected 10 year economic life of the products.  The Company determines the economic life of the products under its license agreements by evaluating similar products the Company has launched or other similar products in the medical industry.  In addition, the Company had a five-year license agreement with Nicolai, GmbH in which the Company was amortizing the license fee on a straight-line basis over the five-year life of the agreement.  This agreement was fully amortized during 2013.
	Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFAST radiofrequency catheters.  In accordance with ASC 605-45, the Company recognizes this revenue gross, with the amount paid to the supplier of the reprocessing service reflected as cost of sales.
	In addition, the Company has reviewed the provisions of ASC 808, Collaborative Arrangements, and the adoption of this ASC has had no impact on the amounts recorded under these agreements.
	In May 2014, the Financial Accounting Standards Board (FASB) issued guidance creating ASC 606, “Revenue from Contracts with Customers.”  The new section will replace ASC 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries.  The new ASC is intended to conform United States revenue accounting principles with concurrently issued International Financial Reporting Standards.  Prior to the guidance, revenue recognition differed between United States practice and those of much of the rest of the world.  The guidance also is intended to enhance disclosures related to disaggregated revenue information.  The updated guidance is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods.  The Company will adopt the new provisions of this accounting standard at the beginning of fiscal year 2017, given that early adoption is not an option.  The Company does not expect adoption will have an impact on the consolidated financial statements.
Shipping and Handling Costs	Shipping and Handling Costs
	In accordance with the ASC 605-45-45, the Company includes shipping and handling revenues in net revenue and shipping and handling costs in cost of goods sold.
Research and Development Costs	Research and Development Costs
	All research and development costs are charged to operations as incurred.
Warranty Costs	Warranty Costs
	Certain of the Company’s products are covered by warranties against defects in material and workmanship for periods of up to 24 months.  The Company records a liability for warranty claims at the time of sale.  The amount of the liability is based on the amount the Company is charged from its original equipment manufacturer to cover the warranty period.  The original equipment manufacturers include a one year warranty with each product sold to the Company.  The Company records a liability for the uncovered warranty period offered to a customer, provided the warranty period offered exceeds the initial one year warranty period covered by the original equipment manufacturers.  Each of the Company’s manufacturer’s warranties covers the first year of service and as a result the Company’s exposure to uncovered warranty periods was minimal at December 31, 2014.
	Warranty provisions and claims for the years ended December 31, 2014, 2013 and 2012, were as follows:
			2014			2013			2012
	Beginning balance		$	23,000		$	29,000		$	23,000
	Warranty provisions			63,000			69,000			57,000
	Warranty claims			(67,000	)		(75,000	)		(51,000	)
	Ending balance		$	19,000		$	23,000		$	29,000
Advertising Costs	Advertising Costs
	The Company follows the policy of charging production costs of advertising to expense as incurred.  Advertising expense was $127,000, $119,000 and $103,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
Stock-Based Compensation	Stock-Based Compensation
	The Company has various types of stock-based compensation plans.  These plans are administered by the Compensation Committee of the Board of Directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.  Refer to Notes 8 and 9 for additional information related to these stock-based compensation plans.
	The following amounts have been recognized as stock-based compensation expense in the Consolidated Statements of Operations:
			2014			2013			2012
	Stock-based compensation included in:
	Cost of goods sold		$	282,000		$	196,000		$	94,000
	Research and development			493,000			373,000			389,000
	Clinical and regulatory			363,000			322,000			313,000
	Sales and marketing			901,000			858,000			941,000
	General and administrative			1,843,000			1,594,000			1,246,000
			$	3,882,000		$	3,343,000		$	2,983,000
	The Company uses the Black-Scholes option-pricing model to estimate fair value of stock-based awards with the following weighted average assumptions:
			2014			2013			2012
	Stock Options:
	Expected life (years)									6.5
	Expected volatility									48	%
	Dividend yield									0	%
	Risk-free interest rate									1.21	%
	Employee Stock Purchase Plan:
	Expected life (years)			2			2			2
	Expected volatility			27	%		29	%		32	%
	Dividend yield			0	%		0	%		0	%
	Risk-free interest rate			0.44	%		0.32	%		0.28	%
	Restricted stock awards fair value is calculated as the market price on the date of grant for the years ended December 31, 2014, 2013 and 2012 and the fair value is amortized on a straight-line basis over the requisite service period of four or nine years for employee awards and one year for board of director awards.  The weighted average fair value of restricted stock awards granted during 2014, 2013 and 2012 was $24.24, $16.31 and $11.10, respectively.
	The weighted average fair value of stock options granted with an exercise price equal to the deemed stock price on the date of grant during 2012 was $5.41.  There were no stock option grants during 2014 and 2013.
	The Company calculates expected volatility for stock options and awards using historical volatility over a period most closely associated with the expected life of the stock option or award.  The Company uses a 10% forfeiture rate for key employees and a 15% forfeiture rate for non-key employees for stock options and awards.  The Company calculates expected volatility for employee stock purchase plan shares using historical volatility over a two-year period.  A two-year period is used to coincide with the maximum two-year offering period under the employee stock purchase plan.  The risk-free rates for the expected terms of the stock options and awards and the employee stock purchase plan is based on the U.S. Treasury yield curve in effect at the time of grant.
Income Taxes	Income Taxes
	Income taxes are accounted for under the liability method.  Deferred income taxes are provided for temporary differences between the financial reporting and the tax bases of assets and liabilities.  Deferred tax assets are reduced by a valuation allowance to the extent that realization of the related deferred tax asset is not assured.  If the Company determines in the future that it is more likely than not that the Company will realize all or a portion of the deferred tax assets, the Company will adjust the valuation allowance in the period the determination is made (see Note 7).
	When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained.  The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.  Tax positions taken are not offset or aggregated with other positions.  Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.  The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
	The Company has recorded ASC 740, Income Taxes, reserves of $1,262,000 and $1,268,000 at December 31, 2014 and 2013.  The impact of tax related interest and penalties is recorded as a component of income tax expense.  At December 31, 2014, the Company has recorded $-0- for the payment of tax related interest and there were no tax penalties or interest recognized in the consolidated statements of earnings.
Net Earnings Per Common Share	Net Earnings Per Common Share
	In accordance with ASC 260, Earnings Per Share, basic net earnings per common share is computed by dividing net earnings by the weighted average common shares outstanding during the periods presented.  Diluted net earnings per common share is computed by dividing net earnings by the weighted average common and potential dilutive common shares outstanding computed in accordance with the treasury stock method.
	The number of shares used in earnings per share computations is as follows for the years ended December 31:
			2014			2013			2012
	Weighted average common shares outstanding— basic			16,891,643			16,412,322			16,003,932
	Effect of dilutive securities			818,919			612,768			451,797
	Weighted average common shares outstanding— diluted			17,710,562			17,025,090			16,455,729
	The effect of dilutive securities in the above table excludes -0-, -0- and 270,000 of options for which the exercise price was higher than the average market price for the years ended December 31, 2014, 2013 and 2012, respectively.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets
	Goodwill is reviewed for impairment annually on December 31st or more frequently if changes in circumstances or the occurrence of events suggest impairment exists using a two-step process.  In step 0, the Company can elect to perform an optional quantitative analysis and based on the results, skip the remaining two steps.  Consistent with prior years, in the current year the Company chose to skip step 0 and perform a quantitative analysis in Step 1.  In step 1, the fair value of each reporting unit is compared to its carrying value, including goodwill.  If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized.  If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would then complete step 2 in order to measure the impairment loss.  In step 2, the Company would calculate the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit.  If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss, in the period identified, equal to the difference.  The Company has concluded that no impairment of goodwill existed as of December 31, 2014.
	Other intangible assets consist of purchased technology, trademark/tradename, developed technology, customer relationships and purchased licenses.  The Company reviewed intangible assets for impairment as changes in circumstances or the occurrence of events suggested the remaining value was not recoverable.
	Amortization on the intangibles is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Trademark/tradename	10 to 11 years
	Purchased and developed technology	9 to 11 years
	Customer relationships	9 years
	Licenses	5 to 10 years
Leases and Deferred Rent	Leases and Deferred Rent
	On December 1, 2014, the Company closed on the purchase of its primary manufacturing facility, a 79,000 square-foot building. This building was leased prior to the purchase.
	On November 30, 2012, the Company closed on the purchase of an office building located next to the building which previously housed the Company’s principal executive offices.  The Company occupies approximately 50,000 square feet of the building and leases the remaining 26,000 square feet of the building to third-party tenants.
	In addition, during the year ended December 31, 2014, the Company also leased additional warehouse and manufacturing space.  Leases are accounted for under the provisions of ASC 840, Leases, which requires that leases be evaluated and classified as operating or capital leases for financial reporting purposes.  As of December 31, 2014, all of the Company’s leases were accounted for as operating leases.  For leases that contain rent escalations, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents paid and the straight-line rent as a deferred rent.  For any lease incentives the Company receives for items such as leasehold improvements, the Company records a deferred credit for the amount of the lease incentive and amortizes it over the lease term, which may or may not equal the amortization period of the leasehold improvements in accordance with ASC 840-20.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Net Revenue by Product Category	The Company uses three product categories for reporting revenue.  The following table sets forth, for the periods indicated, net revenue by product category along with the percent change from the previous year:
			For Years Ended December 31,
			2014						2013						2012
			Net Revenue			Percent Change			Net Revenue			Percent Change			Net Revenue		Percent Change
	Catheter products		$	82,885,000			19	%	$	69,936,000			14	%	$	61,262,000		16	%
	Hemostat products			24,389,000			3	%		23,752,000			5	%		22,676,000		(2	%)
	Vein products			18,392,000			11	%		16,509,000			17	%		14,098,000		34	%
	Total product revenue			125,666,000			14	%		110,197,000			12	%		98,036,000		13	%
	License, royalty & collaboration			433,000			44	%		301,000			(14	%)		350,000		(90	%)
	Total Net Revenue		$	126,099,000			14	%	$	110,498,000			12	%	$	98,386,000		9	%
Inventory	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.   Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following at December 31:
			2014			2013
	Raw materials		$	8,251,000		$	6,386,000
	Work-in-process			1,139,000			926,000
	Finished goods			6,518,000			6,690,000
			$	15,908,000		$	14,002,000
Property, Plant and Equipment	Property, plant and equipment are stated at cost.  Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Manufacturing equipment	1 to 8 years
	Office and computer equipment	1 to 5 years
	Furniture and fixtures	3 to 8 years
	Leasehold improvements	Shorter of useful life or remaining term of the lease
	Research and development equipment	3 to 7 years
	Building improvements	1 to 30 years
	Building	30 years
Warranty Provisions and Claims	Warranty provisions and claims for the years ended December 31, 2014, 2013 and 2012, were as follows:
			2014			2013			2012
	Beginning balance		$	23,000		$	29,000		$	23,000
	Warranty provisions			63,000			69,000			57,000
	Warranty claims			(67,000	)		(75,000	)		(51,000	)
	Ending balance		$	19,000		$	23,000		$	29,000
Share-based Compensation Expense	The following amounts have been recognized as stock-based compensation expense in the Consolidated Statements of Operations:
			2014			2013			2012
	Stock-based compensation included in:
	Cost of goods sold		$	282,000		$	196,000		$	94,000
	Research and development			493,000			373,000			389,000
	Clinical and regulatory			363,000			322,000			313,000
	Sales and marketing			901,000			858,000			941,000
	General and administrative			1,843,000			1,594,000			1,246,000
			$	3,882,000		$	3,343,000		$	2,983,000
Share-based Payment Award, Stock Options, Valuation Assumptions	The Company uses the Black-Scholes option-pricing model to estimate fair value of stock-based awards with the following weighted average assumptions:
			2014			2013			2012
	Stock Options:
	Expected life (years)									6.5
	Expected volatility									48	%
	Dividend yield									0	%
	Risk-free interest rate									1.21	%
	Employee Stock Purchase Plan:
	Expected life (years)			2			2			2
	Expected volatility			27	%		29	%		32	%
	Dividend yield			0	%		0	%		0	%
	Risk-free interest rate			0.44	%		0.32	%		0.28	%
Weighted Average Number of Shares in Earnings Per Share Computations	The number of shares used in earnings per share computations is as follows for the years ended December 31:
			2014			2013			2012
	Weighted average common shares outstanding— basic			16,891,643			16,412,322			16,003,932
	Effect of dilutive securities			818,919			612,768			451,797
	Weighted average common shares outstanding— diluted			17,710,562			17,025,090			16,455,729
Estimated Useful Life of Intangible Assets	Amortization on the intangibles is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Trademark/tradename	10 to 11 years
	Purchased and developed technology	9 to 11 years
	Customer relationships	9 years
	Licenses	5 to 10 years

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Other Intangible Assets [Abstract]
Acquired Intangible Assets	Balances of acquired intangible assets as of December 31, 2014 were as follows:
		Carrying Amount			Accumulated			Net
					Amortization
	Amortizing intangibles:
	Purchased and developed technology	$	8,140,000		$	3,216,000		$	4,924,000
	Purchased licenses		5,050,000			1,515,000			3,535,000
	Trademark / tradename		2,210,000			806,000			1,404,000
	Customer relationships		640,000			204,000			436,000
	Foreign currency translation adjustments		(190,000	)		(55,000	)		(135,000	)
		$	15,850,000		$	5,686,000		$	10,164,000
	Balances of acquired intangible assets as of December 31, 2013 were as follows:
		Carrying Amount			Accumulated			Net
					Amortization
	Amortizing intangibles:
	Purchased and developed technology	$	8,140,000		$	2,360,000		$	5,780,000
	Purchased licenses		5,050,000			1,010,000			4,040,000
	Trademark / tradename		2,210,000			592,000			1,618,000
	Customer relationships		640,000			133,000			507,000
	Foreign currency translation adjustments		16,000			18,000			(2,000	)
		$	16,056,000		$	4,113,000		$	11,943,000
Expected Amortization Expense	Based on the intangibles assets as of December 31, 2014, future amortization expense will be as follows:
	2015	$	1,824,000
	2016		1,817,000
	2017		1,644,000
	2018		1,644,000
	2019		1,352,000
	Thereafter		1,883,000
		$	10,164,000
Goodwill	The following table provides a summary of additions and disposals of goodwill for each reporting period:
	Balance at December 31, 2012	$	10,387,000
	Acquisition of Disposable Vein Hook		59,000
	Foreign currency translation adjustments		86,000
	Balance at December 31, 2013	$	10,532,000
	Foreign currency translation adjustments		(273,000	)
	Balance at December 31, 2014	$	10,259,000

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment consist of the following at December 31:
		2014			2013
	Plant and equipment:
	Manufacturing equipment	$	13,198,000		$	12,019,000
	Buildings		9,930,000			6,407,000
	Office and computer equipment		3,647,000			2,798,000
	Research and development equipment		3,404,000			2,567,000
	Leasehold improvements		2,526,000			2,489,000
	Furniture and fixtures		1,146,000			1,039,000
	Building improvements		790,000			665,000
	Construction-in-process		2,212,000			658,000
			36,853,000			28,642,000
	Less accumulated depreciation and amortization		(16,389,000	)		(14,055,000	)
	Net plant and equipment		20,464,000			14,587,000
	Land		5,201,000			1,600,000
	Net property, plant and equipment	$	25,665,000		$	16,187,000

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Future Minimum Rental Payments for Operating Leases	Future minimum lease commitments under the operating leases as of December 31, 2014 will be as follows:
	2015	$	104,000
		$	104,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Deferred Taxes with Finite Lives	At December 31, 2014, the Company had recorded the following components of deferred taxes with a finite life:
		2014			Expiration Date
	Federal and Minnesota research and development tax credit carryforwards	$	2,681,000		Beginning in 2015
Unrecognized Tax Benefits Roll Forward	A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows:
	Balance at December 31, 2012	$	1,074,000
	Increases as a result of tax positions taken during a prior period		–
	Increases as a result of tax positions taken during the current period		223,000
	Reductions as a result of lapse of the applicable statute of limitations		(29,000	)
	Decreases relating to settlements with taxing authorities		–
	Balance at December 31, 2013	$	1,268,000
	Increases as a result of tax positions taken during a prior period		87,000
	Increases as a result of tax positions taken during the current period		97,000
	Reductions as a result of lapse of the applicable statute of limitations		(32,000	)
	Decreases as a result of state credits expected to expire unutilized		(158,000	)
	Balance at December 31, 2014	$	1,262,000
Deferred Tax Assets and Liabilities	The components of the Company’s deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:
		2014				2013
	Deferred tax assets:
	Research and development (R&D) credit carryforwards	$	2,681,000			$	4,766,000
	Stock-based compensation		2,322,000				1,151,000
	Federal and state AMT credits		993,000				985,000
	Accrued compensation		636,000				578,000
	Inventory reserve		522,000				609,000
	Net operating loss carryforwards		471,000				–
	Depreciation and amortization		158,000				624,000
	Deferred revenue		154,000				229,000
	Foreign operations net operating loss carryforwards and timing differences		53,000				96,000
	Legal settlement		–				196,000
	Other		104,000				115,000
	Gross deferred tax assets		8,094,000				9,349,000
	Deferred tax liability relating to amortization		(803,000	)			(584,000	)
	Net deferred taxes assets before reserve for uncertain tax positions and valuation allowances		7,291,000				8,765,000
	Reserve for uncertain tax positions		(346,000	)			(882,000	)
	Less valuation allowances		(1,173,000	)			(144,000	)
	Net deferred tax assets	$	5,772,000			$	7,739,000
			2014				2013
	Deferred taxes recorded on the balance sheet:
	Deferred tax assets – current	$	3,681,000			$	6,000,000
	Deferred tax assets – long-term		2,894,000				1,739,000
	Deferred tax assets		6,575,000				7,739,000
	Deferred tax liabilities – long-term		803,000				–
	Net deferred tax assets	$	5,772,000			$	7,739,000
Effective Income Tax Rate Reconciliation	Reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		2014				2013			2012
	Tax at federal statutory rate		35	%			34	%		34	%
	State income taxes, net of federal benefit		2.8				4.4			6.2
	Permanent differences		(1.3	)			(0.8	)		1.9
	Change in valuation reserve		4				0.2			0.2
	R&D credits generated		(2.4	)			(4.2	)		(1.1	)
	Reserve for uncertain tax positions		(1.8	)			0.9			0.1
	Foreign operations tax rate difference		(0.8	)			(0.5	)		(0.7	)
	Disallowed federal R&D credits at 12.31.12		–				(1.9	)		–
	Other adjustments		0.5				(1.0	)		(3.0	)
	Effective income tax rate		36	%			31.1	%		37.6	%
		2014				2013			2012
	Current taxes		29.6	%			26.8	%		12.8	%
	Deferred taxes		9.9				6.6			26.1
	Benefit from foreign operation tax rates		(0.8	)			(0.5	)		(0.7	)
	Benefit from domestic manufacturers deduction		(2.7	)			(1.8	)		(0.6	)
	Effective income tax rate		36	%			31.1	%		37.6	%

Stock_Options_and_Restricted_S1

Stock Options and Restricted Shares (Tables)	12 Months Ended
	Dec. 31, 2014
Stock Options and Restricted Shares [Abstract]
Option Activity	Option activity is summarized as follows:
			Shares				Plan Options				Exercise				Weighted Average Exercise				Aggregate
			Available				Outstanding				Price				Price				Intrinsic
			for Grant																Value
			(exclusive of restricted
			shares issued)
	Balance at December 31, 2011			4,327,000				801,000			$	0.78–$11.72			$	7.38
	Shares reserved			(1,900,000	)			–				–				–
	Granted			(500,000	)			500,000				11.03– 15.03				12.89
	Exercised			–				(158,000	)			0.84– 10.28				3.1
	Forfeited			–				–				–				–
	Expired			–				–				–				–
	Balance at December 31, 2012			1,927,000				1,143,000			$	0.78–$15.03			$	10.38
	Shares reserved			500,000				–				–				–
	Granted			–				–				–				–
	Exercised			–				(354,000	)			0.78– 11.72				7.86
	Forfeited			–				–				–				–
	Expired			1,000				(1,000	)			0.84– 5.74				5.38
	Balance at December 31, 2013			2,428,000				788,000			$	6.36–$15.03			$	11.52
	Shares reserved			–				–				–				–
	Granted			–				–				–				–
	Exercised			–				(102,000	)			6.74– 10.89				9.52
	Forfeited			–				–				–				–
	Expired			4,000				(4,000	)			6.74– 10.10				8.61
	Balance at December 31, 2014			2,432,000				682,000			$	6.36–$15.03			$	11.84			$	10,440,000
	Exercisable at December 31, 2014							410,000							$	10.4			$	6,870,000
Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2014:
					Options Outstanding												Options Exercisable
	Range of				Outstanding				Weighted				Weighted				Exercisable				Weighted
	Exercise Prices				as of				Average				Average				as of				Average
					December 31,				Remaining Contractual Life				Exercise Price				December 31,				Exercise Price
					2014												2014
	$	6.36–$ 7.88				70,000				3.2			$	6.81				70,000			$	6.81
		7.89– 10.98				82,000				3.3				9.74				82,000				9.74
		10.99– 11.72				170,000				6.9				11.34				168,000				11.34
		11.73– 12.03				90,000				7.1				12.03				90,000				12.03
		12.04– 13.03				90,000				7.1				13.03				–				–
		13.04– 15.03				180,000				7.1				14.53				–				–
						682,000				6.2			$	11.84				410,000			$	10.4
Restricted Share Activity	Restricted share activity is summarized as follows:
			Shares				Weighted Average
			Outstanding				Grant Date Fair
							Value
	Balance at December 31, 2011			567,000			$	9.43
	Granted			245,000				11.1
	Vested			(167,000	)			8.12
	Forfeited			(32,000	)			10.67
	Balance at December 31, 2012			613,000			$	10.39
	Granted			199,000				16.31
	Vested			(208,000	)			9.96
	Forfeited			(16,000	)			11.22
	Balance at December 31, 2013			588,000			$	12.52
	Granted			175,000				24.24
	Vested			(247,000	)			11
	Forfeited			(9,000	)			17.23
	Balance at December 31, 2014			507,000			$	17.24

Concentrations_of_Credit_and_O1

Concentrations of Credit and Other Risks (Tables)	12 Months Ended
	Dec. 31, 2014
Concentrations of Credit and Other Risks [Abstract]
Product Revenue by Geographic Destination as a Percentage of Total Product Revenues	Product revenue by geographic destination as a percentage of total product revenues were as follows for the years ended December 31:
		2014			2013			2012
	Domestic		82	%		85	%		84	%
	Foreign		18			15			16

Business_Combinations_and_Asse1

Business Combinations and Asset Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Shepherd Scientific, Inc. [Member]
Business Acquisition [Line Items]
Purchase Price Allocation	The purchase price was allocated as follows:
	Purchased technology	$	170,000
	Inventory and equipment		70,000
	Other intangibles		50,000
	Goodwill		210,000
		$	500,000
St. Jude Medical, Cardiology Division Inc [Member]
Business Acquisition [Line Items]
Purchase Price Allocation	The purchase price was allocated as follows:
	Purchased technology	$	850,000
	Other intangibles		500,000
	Inventory and equipment		189,000
	Goodwill		1,461,000
		$	3,000,000
Accumed Systems, Inc [Member]
Business Acquisition [Line Items]
Purchase Price Allocation	The purchase price was allocated as follows:
	Purchased technology	$	740,000
	Other intangibles		190,000
	Inventory and equipment		8,000
	Goodwill		562,000
		$	1,500,000

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) [Abstract]
Quarterly Financial Data	2014	Fourth Quarter		Third Quarter		Second Quarter		First Quarter
	Net revenue:
	Product	$	33,449	$	31,766	$	30,606	$	29,845
	License, royalty & collaboration		137		163		71		62
	Total net revenue		33,586		31,929		30,677		29,907
	Selected costs and expenses:
	Costs of goods sold		11,542		10,291		10,283		9,583
	Operating earnings		5,312		5,213		5,031		4,371
	Net earnings		4,160		2,570		3,205		2,799
	Basic net earnings per share	$	0.25	$	0.15	$	0.19	$	0.17
	Diluted net earnings per share	$	0.23	$	0.15	$	0.18	$	0.16
	2013	Fourth Quarter		Third Quarter		Second Quarter		First Quarter
	Net revenue:
	Product	$	29,000	$	27,926	$	27,294	$	25,977
	License		72		83		59		87
	Total net revenue		29,072		28,009		27,353		26,064
	Selected costs and expenses:
	Costs of goods sold		9,724		9,197		8,538		8,697
	Operating earnings		4,731		4,020		4,442		2,904
	Net earnings		3,537		2,672		2,808		2,125
	Basic net earnings per share	$	0.21	$	0.16	$	0.17	$	0.13
	Diluted net earnings per share	$	0.2	$	0.16	$	0.17	$	0.13

Description_of_Business_Detail

Description of Business (Details)	Dec. 31, 2014
	Category
Description of Business [Abstract]
Number of product categories	3

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Category								Category
Product Information [Line Items]
Number of product categories	3								3
Total net revenue	$33,586,000	$31,929,000	$30,677,000	$29,907,000	$29,072,000	$28,009,000	$27,353,000	$26,064,000	$126,099,000	$110,498,000	$98,386,000
Total revenue, percentage change (in hundredths)									14.00%	12.00%	9.00%
Statement of Other Comprehensive Income [Abstract]
Foreign currency translation adjustment									-725,000	-1,000
Valuation and Qualifying Accounts Disclosure [Line Items]
Number of days before considered past due									60 days
Restocking charge (in hundredths)									20.00%
Balance at End of Year	300,000				200,000				300,000	200,000	185,000	150,000
Inventories [Abstract]
Raw materials	8,251,000				6,386,000				8,251,000	6,386,000
Work in process	1,139,000				926,000				1,139,000	926,000
Finished goods	6,518,000				6,690,000				6,518,000	6,690,000
Total inventory	15,908,000				14,002,000				15,908,000	14,002,000
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at End of Year	220,000				150,000				220,000	150,000
Sales Return Allowance [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at End of Year	80,000				50,000				80,000	50,000	55,000	30,000
Catheter Products [Member]
Product Information [Line Items]
Total net revenue									82,885,000	69,936,000	61,262,000
Total revenue, percentage change (in hundredths)									19.00%	14.00%	16.00%
Hemostat Products [Member]
Product Information [Line Items]
Total net revenue									24,389,000	23,752,000	22,676,000
Total revenue, percentage change (in hundredths)									3.00%	5.00%	-2.00%
Vein Products and Services [Member]
Product Information [Line Items]
Total net revenue									18,392,000	16,509,000	14,098,000
Total revenue, percentage change (in hundredths)									11.00%	17.00%	34.00%
Total Product Revenue [Member]
Product Information [Line Items]
Total net revenue									125,666,000	110,197,000	98,036,000
Total revenue, percentage change (in hundredths)									14.00%	12.00%	13.00%
License, Royalty and Collaboration [Member]
Product Information [Line Items]
Total net revenue									$433,000	$301,000	$350,000
Total revenue, percentage change (in hundredths)									44.00%	-14.00%	-90.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies, Part Two (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warranty costs [Abstract]
Standard product warranty timeframe	24 months
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$23,000	$29,000	$23,000
Warranty provisions	63,000	69,000	57,000
Warranty claims	-67,000	-75,000	-51,000
Ending balance	19,000	23,000	29,000
Advertising Costs [Abstract]
Advertising expense	$127,000	$119,000	$103,000
Thrombi Pad [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years
Thrombi Paste [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years
Thrombi Gel [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years
Nicolai, GmbH [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	5 years
Minimum [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	9 years
Maximum [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	11 years
Manufacturing Equipment [Member] | Minimum [Member]
Property and Equipment [Line Items]
Useful life	1 year
Manufacturing Equipment [Member] | Maximum [Member]
Property and Equipment [Line Items]
Useful life	8 years
Office and Computer Equipment [Member] | Minimum [Member]
Property and Equipment [Line Items]
Useful life	1 year
Office and Computer Equipment [Member] | Maximum [Member]
Property and Equipment [Line Items]
Useful life	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property and Equipment [Line Items]
Useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property and Equipment [Line Items]
Useful life	8 years
Leasehold Improvements [Member]
Property and Equipment [Line Items]
Useful life of leasehold improvements	Shorter of useful life or remaining term of the lease
Research and Development Equipment [Member] | Minimum [Member]
Property and Equipment [Line Items]
Useful life	3 years
Research and Development Equipment [Member] | Maximum [Member]
Property and Equipment [Line Items]
Useful life	7 years
Building Improvements [Member] | Minimum [Member]
Property and Equipment [Line Items]
Useful life	1 year
Building Improvements [Member] | Maximum [Member]
Property and Equipment [Line Items]
Useful life	30 years
Building [Member]
Property and Equipment [Line Items]
Useful life	30 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies, Part Three (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$3,882,000	$3,343,000	$2,983,000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted, weighted average grant date fair value (in dollars per share)	$24.24	$16.31	$11.10
Stock options granted, weighted average exercise price (in dollars per share)			$5.41
Expected forfeiture rate for key employees (in hundredths)	10.00%
Expected forfeiture rate for non-key employees (in hundredths)	15.00%
Income Tax Uncertainties [Abstract]
Unrecognized tax benefits	1,262,000	1,268,000	1,074,000
Net income per share [Abstract]
Weighted average common shares outstanding - basic (in shares)	16,891,643	16,412,322	16,003,932
Effect of diluted securities (in shares)	818,919	612,768	451,797
Weighted average common shares outstanding - diluted (in shares)	17,710,562	17,025,090	16,455,729
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	270,000
Manufacturing Facility [Member]
Leases and Deferred Rent [Abstract]
Area of the manufacturing facility (in square feet)	79,000
Office Building [Member]
Leases and Deferred Rent [Abstract]
Area occupied by the company (in square feet)	50,000
Area occupied by current tenants (in square feet)	26,000
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	9 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	11 years
Trademark/Tradename [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Trademark/Tradename [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	11 years
Purchased Technology [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	9 years
Purchased Technology [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	11 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	9 years
Licenses [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	5 years
Licenses [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Stock Options and Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life			6 years 6 months
Expected volatility (in hundredths)			48.00%
Dividend yield (in hundredths)			0.00%
Risk free interest rate (in hundredths)			1.21%
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years	2 years
Expected volatility (in hundredths)	27.00%	29.00%	32.00%
Dividend yield (in hundredths)	0.00%	0.00%	0.00%
Risk free interest rate (in hundredths)	0.44%	0.32%	0.28%
Cost of Goods Sold [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	282,000	196,000	94,000
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	493,000	373,000	389,000
Clinical and Regulatory [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	363,000	322,000	313,000
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	901,000	858,000	941,000
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$1,843,000	$1,594,000	$1,246,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 11, 2012	Dec. 21, 2012
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	$1,642,000	$1,572,000	$1,393,000
Carrying amount	15,850,000	16,056,000
Accumulated amortization	5,686,000	4,113,000
Net	10,164,000	11,943,000
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2015	1,824,000
2016	1,817,000
2017	1,644,000
2018	1,644,000
2019	1,352,000
Thereafter	1,883,000
Total	10,164,000	11,943,000
Goodwill [Abstract]
Beginning balance	10,532,000	10,387,000
Foreign currency translation adjustments	-273,000	86,000
Ending balance	10,259,000	10,532,000	10,387,000
Accumed Systems, Inc [Member]
Goodwill [Abstract]
Beginning balance				562,000
Ending balance				562,000
Shepherd Scientific, Inc. [Member]
Goodwill [Abstract]
Beginning balance					210,000
Ending balance					210,000
Disposable Vein Hook [Member]
Goodwill [Abstract]
Purchased licenses & acquisitions		59,000
Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives	11 years
Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives	9 years
Purchased and Developed Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying amount	8,140,000	8,140,000
Accumulated amortization	3,216,000	2,360,000
Net	4,924,000	5,780,000
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	4,924,000	5,780,000
Purchased Licenses [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying amount	5,050,000	5,050,000
Accumulated amortization	1,515,000	1,010,000
Net	3,535,000	4,040,000
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	3,535,000	4,040,000
Purchased Licenses [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Purchased Licenses [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives	5 years
Trademark/Tradename [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying amount	2,210,000	2,210,000
Accumulated amortization	806,000	592,000
Net	1,404,000	1,618,000
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	1,404,000	1,618,000
Trademark/Tradename [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives	11 years
Trademark/Tradename [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives	9 years
Carrying amount	640,000	640,000
Accumulated amortization	204,000	133,000
Net	436,000	507,000
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	436,000	507,000
Foreign Currency Translation Adjustments [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying amount	-190,000	16,000
Accumulated amortization	-55,000	18,000
Net	-135,000	-2,000
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	($135,000)	($2,000)

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property and Equipment [Line Items]
Plant and Equipment, Gross	$36,853,000	$28,642,000
Less accumulated depreciation and amortization	-16,389,000	-14,055,000
Net plant and equipment	20,464,000	14,587,000
Land	5,201,000	1,600,000
Net property, plant and equipment	25,665,000	16,187,000
Manufacturing Equipment [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	13,198,000	12,019,000
Buildings [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	9,930,000	6,407,000
Office and Computer Equipment [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	3,647,000	2,798,000
Research and Development Equipment [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	3,404,000	2,567,000
Leasehold Improvements [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	2,526,000	2,489,000
Furniture and Fixtures [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	1,146,000	1,039,000
Building Improvements [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	790,000	665,000
Construction in Progress [Member]
Property and Equipment [Line Items]
Plant and Equipment, Gross	$2,212,000	$658,000

Lines_of_Credit_Details

Lines of Credit (Details) (Lines of Credit [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Lines of Credit [Member]
Line of Credit Facility [Line Items]
Credit agreement period	1 year
Maximum credit limit	$10,000,000
Revolving credit agreement, initiation date	21-Dec-09
Revolving credit agreement, expiration date	31-Dec-13

Leases_Details

Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	sqft
Leases [Abstract]
Rent expense	$1,010,000	$1,350,000	$1,273,000
Future Minimum Payments Due [Abstract]
2015	104,000
Total	$104,000
Operating Leases [Line Items]
Number of square-feet in the buildings under an operating lease	79,000
Minnesota [Member]
Operating Leases [Line Items]
Number of buildings under lease	1
Number of square-feet in the buildings under an operating lease	26,000
Ireland [Member]
Operating Leases [Line Items]
Number of buildings under lease	1
Number of square-feet in the buildings under an operating lease	1,150

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Components of Deferred Taxes with Finite Life [Abstract]
Federal and Minnesota research and development tax credit carryforwards		$2,681,000
Federal and Minnesota research and development tax credit carryforwards, Earliest Expiration Date		31-Dec-15
Allowance relating to research and development tax credit carryforwards		1,173,000	144,000	1,434,000
Tax Related [Line Items]
Income tax expense (benefit)		7,178,000	4,941,000	5,983,000
Earnings (loss) before income tax		19,912,000	16,083,000	15,892,000
Increase (decrease) in valuation allowance	867,000	1,029,000	-1,290,000	-683,000
Reduction of the related research and development credit carryforward deferred tax asset		916,000
Stock option and employee stock purchase plan tax benefits against "additional paid-in capital" and reduced taxes payable		1,823,000	2,084,000	1,135,000
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance		1,268,000	1,074,000
Increases as a result of tax positions taken during a prior period		87,000	0
Increases as a result of tax positions taken during the current period		97,000	223,000
Reductions as a result of lapse of the applicable statute of limitations		-32,000	-29,000
Decreases relating to settlements with taxing authorities		-158,000	0
Ending balance		1,262,000	1,268,000	1,074,000
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Tax at federal statutory rate (in hundredths)		35.00%	34.00%	34.00%
State income taxes, net of federal benefit (in hundredths)		2.80%	4.40%	6.20%
Permanent differences (in hundredths)		-1.30%	-0.80%	1.90%
Change in valuation reserve (in hundredths)		4.00%	0.20%	0.20%
R&D credits generated (in hundredths)		-2.40%	-4.20%	-1.10%
Reserve for uncertain tax positions (in hundredths)		-1.80%	0.90%	0.10%
Foreign operations tax rate difference		-0.80%	-0.50%	-0.70%
Disallowed federal R&D credits at 12.31.12		0.00%	-1.90%	0.00%
Other adjustments (in hundredths)		0.50%	-1.00%	-3.00%
Effective income tax rate (in hundredths)		36.00%	31.10%	37.60%
Current taxes (in hundredths)		29.60%	26.80%	12.80%
Deferred taxes (in hundredths)		9.90%	6.60%	26.10%
Benefit from foreign operation tax rates		-0.80%	-0.50%	-0.70%
Benefit from domestic manufacturers deduction		-2.70%	-1.80%	-0.60%
Deferred Tax Assets [Abstract]
Research and development (R&D) credit carryforwards		2,681,000	4,766,000
Stock-based compensation		2,322,000	1,151,000
Federal and state AMT credits		993,000	985,000
Accrued compensation		636,000	578,000
Inventory reserve		522,000	609,000
Net operating loss carryforwards		471,000	0
Depreciation and amortization		158,000	624,000
Deferred revenue		154,000	229,000
Foreign operations net operating loss carryforwards and timing differences		53,000	96,000
Legal settlement		0	196,000
Other		104,000	115,000
Gross deferred tax assets		8,094,000	9,349,000
Deferred tax liability relating to amortization		-803,000	-584,000
Net deferred taxes assets before reserve for uncertain tax positions and valuation allowances		7,291,000	8,765,000
Reserve for uncertain tax positions		-346,000	-882,000
Less Valuation allowances		-1,173,000	-144,000
Net deferred tax asset		5,772,000	7,739,000
Deferred taxes recorded on the balance sheet [Abstract]
Net deferred tax assets - current		3,681,000	6,000,000
Net deferred tax assets - long-term		2,894,000	1,739,000
Net deferred tax assets		6,575,000	7,739,000
Deferred tax liabilities-long-term		803,000	0
Domestic [Member]
Tax Related [Line Items]
Earnings (loss) before income tax		19,488,000	16,080,000	15,594,000
Foreign [Member]
Tax Related [Line Items]
Earnings (loss) before income tax		$424,000	($108,000)	$298,000

Stock_Options_and_Restricted_S2

Stock Options and Restricted Shares (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for Stock Option Plan	5,500,000
Weighted Average Exercise Price [Roll Forward]
Granted, weighted average exercise price (in dollars per share)			$5.41
Weighted Average Grant Date Fair Value [Roll Forward]
Granted (in dollars per share)	$24.24	$16.31	$11.10
Shares available for grant, balance at end of period (in shares)	859,000
Unrecognized compensation costs for stock options	$863,000
Expected forfeiture rate for key employees (in hundredths)	10.00%
Expected forfeiture rate for non-key employees (in hundredths)	15.00%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding as of end of period (in shares)	682,000
Options Outstanding, Weighted Average Remaining Contractual Life	6 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$11.84
Options Exercisable as of end of period (in shares)	410,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$10.40
$6.36 to $7.88 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	$6.36
Exercise price range, upper range limit (in dollars per share)	$7.88
Options Outstanding as of end of period (in shares)	70,000
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$6.81
Options Exercisable as of end of period (in shares)	70,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$6.81
$7.89 to $10.98 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	$7.89
Exercise price range, upper range limit (in dollars per share)	$10.98
Options Outstanding as of end of period (in shares)	82,000
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$9.74
Options Exercisable as of end of period (in shares)	82,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$9.74
$10.99 to $11.72 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	$10.99
Exercise price range, upper range limit (in dollars per share)	$11.72
Options Outstanding as of end of period (in shares)	170,000
Options Outstanding, Weighted Average Remaining Contractual Life	6 years 10 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$11.34
Options Exercisable as of end of period (in shares)	168,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$11.34
$11.73 to $12.03 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	$11.73
Exercise price range, upper range limit (in dollars per share)	$12.03
Options Outstanding as of end of period (in shares)	90,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$12.03
Options Exercisable as of end of period (in shares)	90,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$12.03
$12.04 to $13.03 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	$12.04
Exercise price range, upper range limit (in dollars per share)	$13.03
Options Outstanding as of end of period (in shares)	90,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$13.03
Options Exercisable as of end of period (in shares)	0
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$0
$13.04 to $15.03 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	$13.04
Exercise price range, upper range limit (in dollars per share)	$15.03
Options Outstanding as of end of period (in shares)	180,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$14.53
Options Exercisable as of end of period (in shares)	0
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$0
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of successive periods to awards vesting	5
Escalation (in dollars per share)	$1
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms of award	10 years
Vesting period, incentive stock options	4 years
Award vesting period, nonqualified stock options	1 year
Number of months after employment until the options are terminated	3 months
Vesting period for options	1 year
Forfeiture rate on options granted (in hundredths)	0.00%
Plan Options Outstanding [Roll Forward]
Balance at beginning of year (in shares)	788,000	1,143,000	801,000
Shares reserved (in shares)	0	0	0
Granted (in shares)	0	0	500,000
Exercised (in shares)	-102,000	-354,000	-158,000
Forfeited (in shares)	0	0	0
Expired (in shares)	-4,000	-1,000	0
Balance at end of year (in shares)	682,000	788,000	1,143,000
Weighted Average Exercise Price [Roll Forward]
Balance at beginning of year, weighted average exercise price (in dollars per share)	$11.52	$10.38	$7.38
Reserved, weighted average exercise price (in dollars per share)	$0	$0	$0
Granted, weighted average exercise price (in dollars per share)	$0	$0	$12.89
Exercised, weighted average exercise price (in dollars per share)	$9.52	$7.86	$3.10
Forfeited, weighted average exercise price (in dollars per share)	$0	$0	$0
Expired, weighted average exercise price (in dollars per share)	$8.61	$5.38	$0
Balance at end of period, weighted average exercise price (in dollars per share)	$11.84	$11.52	$10.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding balance, aggregate intrinsic value	10,440,000
Exercisable at end of period (in shares)	410,000
Exercisable, weighted average exercise price (in dollars per share)	$10.40
Exercisable, intrinsic value at end of period	6,870,000
Exercise price, reserved (in dollars per share)	$0	$0	$0
Exercise price, forfeited (in dollars per share)	$0	$0	$0
Options, exercisable, weighted average remaining contractual term	5 years 7 months 6 days
Total intrinsic value of options exercised	1,595,000	3,057,000	1,464,000
Weighted Average Grant Date Fair Value [Roll Forward]
Shares available for grant, balance at beginning (in shares)	2,428,000	1,927,000	4,327,000
Shares reserved (in shares)	0	500,000	-1,900,000
Granted (in shares)	0	0	-500,000
Exercised (in shares)	0	0	0
Forfeited (in shares)	0	0	0
Expired (in shares)	4,000	1,000	0
Shares available for grant, balance at end of period (in shares)	2,432,000	2,428,000	1,927,000
Weighted average period for recognizing unrecognized compensation costs	1 year 1 month 6 days
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Exercise price, beginning balance (in dollar per share)	$6.36	$0.78	$0.78
Exercise price, granted (in dollars per share)			$11.03
Exercise price, exercised (in dollars per share)	$6.74	$0.78	$0.84
Exercise price, expired (in dollars per share)	$6.74	$0.84
Exercise price, ending balance (in dollar per share)	$6.36	$6.36	$0.78
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Exercise price, beginning balance (in dollar per share)	$15.03	$15.03	$11.72
Exercise price, granted (in dollars per share)			$15.03
Exercise price, exercised (in dollars per share)	$10.89	$11.72	$10.28
Exercise price, expired (in dollars per share)	$10.10	$5.74
Exercise price, ending balance (in dollar per share)	$15.03	$15.03	$15.03
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period for options	1 year
Share Outstanding [Roll Forward]
Balance at beginning of period (in shares)	588,000	613,000	567,000
Granted (in shares)	175,000	199,000	245,000
Vested (in shares)	-247,000	-208,000	-167,000
Forfeited (in shares)	-9,000	-16,000	-32,000
Balance at end of period (in shares)	507,000	588,000	613,000
Weighted Average Grant Date Fair Value [Roll Forward]
Balance at beginning of period (in dollars per share)	$12.52	$10.39	$9.43
Granted (in dollars per share)	$24.24	$16.31	$11.10
Vested (in dollars per share)	$11	$9.96	$8.12
Forfeited (in dollars per share)	$17.23	$11.22	$10.67
Balance at end of period (in dollars per share)	$17.24	$12.52	$10.39
Shares available for grant, balance at end of period (in shares)	1,573,000
Unrecognized compensation costs for restricted shares	$2,576,000
Weighted average period for recognizing unrecognized compensation costs	1 year 5 months 19 days
Expected forfeiture rate for directors (in hundredths)	0.00%
Expected forfeiture rate for key employees (in hundredths)	10.00%
Expected forfeiture rate for non-key employees (in hundredths)	15.00%

Employee_Stock_Purchase_Plan_D

Employee Stock Purchase Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Purchase Plan [Abstract]
Number of reserved shares (in shares)	2,700,000
Minimum percentage of compensation to contribute (in hundredths)	1.00%
Maximum percentage of compensation to contribute (in hundredths)	10.00%
Discount to market (in hundredths)	15.00%
Maximum number of shares available to purchase per purchasing period, per employee (in shares)	2,000
Stock issued (in shares)	103,500	124,100	114,100
Shares available for issuance (in shares)	862,000
Aggregate compensation cost not yet recognized, ESPP	$381,000
Period for recognition	0 years 9 months 11 days

Employee_Retirement_Savings_Pl1

Employee Retirement Savings Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Retirement Savings Plan [Abstract]
Employees maximum contribution percentage of annual compensation (in hundredths)	50.00%
Employer matching contribution, percent (in hundredths)	25.00%
Maximum annual contribution per employee, matched by employer, percent (in hundredths)	10.00%
Expense recorded	$408,000	$243,000	$204,000

Concentrations_of_Credit_and_O2

Concentrations of Credit and Other Risks (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]
Threshold for reporting customers revenues by customer (in hundredths)	10.00%	10.00%	10.00%
Threshold for reporting customers gross receivables by customer (in hundredths)	10.00%	10.00%
Domestic [Member] | Product Revenue [Member]
Concentration Risk [Line Items]
Concentration risk (in hundredths)	82.00%	85.00%	84.00%
Foreign [Member] | Product Revenue [Member]
Concentration Risk [Line Items]
Concentration risk (in hundredths)	18.00%	15.00%	16.00%

Related_Party_Activity_Details

Related Party Activity (Details) (Officer [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Officer [Member]
Related Party Transaction [Line Items]
Revenue from related parties	$311,000	$361,000	$451,000
Accounts receivable	35,000	14,000
Purchases from related party	18,000	10,000	10,000
Accounts payable	$0	$0

Dependence_on_Key_Suppliers_De

Dependence on Key Suppliers (Details)	12 Months Ended
	Dec. 31, 2014
Kings Pharmaceuticals [Abstract]
Initial agreement period	10 years
Contract extension period	1 year
Period of written notice to supplier	5 years

Commitments_and_Contingencies_

Commitments and Contingencies (Details)

3 Months Ended

12 Months Ended

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Apr. 01, 2008

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Stock Repurchase Plan [Member]

Governmental Proceedings [Member]

King Agreements [Member]

King Agreements [Member]

King Agreements [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Loss Contingencies [Line Items]

Repurchase of common stock under stock repurchase agreement

$20,000,000

Repurchase of common stock under stock repurchase agreement (in shares)

33,401

Average price per share (in dollars per share)

$24.52

Amortization period for license fee

10 years

5 years

Amortization of license fee

204,000

205,000

204,000

0

36,000

146,000

Unamortized license fee

406,000

610,000

815,000

0

0

36,000

500,000

Governmental Proceedings [Abstract]

Total U.S. sales, maximum

33,449,000

31,766,000

30,606,000

29,845,000

29,000,000

27,926,000

27,294,000

25,977,000

125,666,000

110,197,000

98,036,000

534,000

Total U.S. sales, percentage (in hundredths)

0.10%

Damages from product defects to government

20,000,000

Payment on settlement of litigation

$520,000

Business_Combinations_and_Asse2

Business Combinations and Asset Acquisitions (Details) (USD $)	12 Months Ended			0 Months Ended			29 Months Ended	0 Months Ended	31 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 21, 2012	Apr. 17, 2013	Aug. 16, 2012	Dec. 31, 2014	Jun. 11, 2012	Dec. 31, 2014	Jan. 06, 2012
Purchase price allocation [Abstract]
Acquired finite-lived intangible asset, amount	$15,850,000	$16,056,000
Business acquisition, cost of acquired entity, cash paid	0	820,000	7,500,000
Purchase price asset allocation [Abstract]
Goodwill	10,259,000	10,532,000	10,387,000				10,259,000		10,259,000
Trademarks [Member]
Purchase price allocation [Abstract]
Acquired finite-lived intangible asset, amount	2,210,000	2,210,000
Customer Relationships [Member]
Purchase price allocation [Abstract]
Acquired finite-lived intangible asset, amount	640,000	640,000
Licenses [Member]
Purchase price allocation [Abstract]
Acquired finite-lived intangible asset, amount	5,050,000	5,050,000
Shepherd Scientific, Inc. [Member]
Purchase price allocation [Abstract]
Business acquisition, cost of acquired entity, purchase price, total				500,000
Business acquisition, purchase price allocation, liabilities assumed				0
Purchase price asset allocation [Abstract]
Purchased technology				170,000
Inventory and equipment				70,000
Other intangibles				50,000
Goodwill				210,000
Total asset purchase price allocation				500,000
Estimated useful life of intangible assets	9 years
Shepherd Scientific, Inc. [Member] | Technology [Member]
Purchase price asset allocation [Abstract]
Estimated useful life of intangible assets	9 years
Shepherd Scientific, Inc. [Member] | Trademarks [Member]
Purchase price asset allocation [Abstract]
Other intangibles				30,000
Estimated useful life of intangible assets	10 years
Shepherd Scientific, Inc. [Member] | Customer Relationships [Member]
Purchase price asset allocation [Abstract]
Other intangibles				20,000
Estimated useful life of intangible assets	9 years
St. Jude Medical, Cardiology Division, Inc. [Member]
Purchase price allocation [Abstract]
Business acquisition, cost of acquired entity, purchase price, total						3,000,000
Business acquisition, cost of acquired entity, cash paid					750,000	2,250,000
Business acquisition, purchase price allocation, liabilities assumed						0
Purchase price asset allocation [Abstract]
Purchased technology						850,000
Inventory and equipment						189,000
Other intangibles						500,000
Goodwill						1,461,000
Total asset purchase price allocation						3,000,000
Estimated useful life of intangible assets	9 years
Additional revenue relating to Venture Wire Control Catheter							3,448,000
Additional net earnings relating to Venture Wire Control Catheter							2,197,000
St. Jude Medical, Cardiology Division, Inc. [Member] | Technology [Member]
Purchase price asset allocation [Abstract]
Estimated useful life of intangible assets	9 years
St. Jude Medical, Cardiology Division, Inc. [Member] | Trademarks [Member]
Purchase price asset allocation [Abstract]
Other intangibles						220,000
Estimated useful life of intangible assets	10 years
St. Jude Medical, Cardiology Division, Inc. [Member] | Customer Relationships [Member]
Purchase price asset allocation [Abstract]
Other intangibles						280,000
Estimated useful life of intangible assets	9 years
Accumed Systems, Inc [Member]
Purchase price allocation [Abstract]
Business acquisition, cost of acquired entity, purchase price, total								1,500,000
Business acquisition, purchase price allocation, liabilities assumed								0
Purchase price asset allocation [Abstract]
Purchased technology								740,000
Inventory and equipment								8,000
Other intangibles								190,000
Goodwill								562,000
Total asset purchase price allocation								1,500,000
Estimated useful life of intangible assets	9 years
Additional revenue relating to Accumed wrist positioning splint products									2,497,000
Additional net earnings relating to Accumed wrist positioning splint products									1,247,000
Accumed Systems, Inc [Member] | Technology [Member]
Purchase price asset allocation [Abstract]
Estimated useful life of intangible assets	9 years
Accumed Systems, Inc [Member] | Trademarks [Member]
Purchase price asset allocation [Abstract]
Other intangibles								100,000
Estimated useful life of intangible assets	10 years
Accumed Systems, Inc [Member] | Customer Relationships [Member]
Purchase price asset allocation [Abstract]
Other intangibles								90,000
Estimated useful life of intangible assets	9 years
Dr. Pedro Silva and Affiliates [Member]
Purchase price allocation [Abstract]
Acquired indefinite-lived intangible asset, amount										3,250,000
Dr. Pedro Silva and Affiliates [Member] | Licenses [Member]
Purchase price asset allocation [Abstract]
Estimated useful life of intangible assets	10 years
Northeast Scientific [Member]
Purchase price allocation [Abstract]
Acquired finite-lived intangible asset, amount	900,000
Amount paid For exclusive rights	500,000						500,000		500,000
Term of agreement	8 years
Amount accrued for exclusive rights	400,000						400,000		400,000
Northeast Scientific [Member] | Prior Approval [Member]
Purchase price allocation [Abstract]
Amount paid For exclusive rights	500,000						500,000		500,000
Northeast Scientific [Member] | After Approval [Member]
Purchase price allocation [Abstract]
Amount paid For exclusive rights	$400,000						$400,000		$400,000

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net revenue [Abstract]
Product	$33,449,000	$31,766,000	$30,606,000	$29,845,000	$29,000,000	$27,926,000	$27,294,000	$25,977,000	$125,666,000	$110,197,000	$98,036,000
License	137,000	163,000	71,000	62,000	72,000	83,000	59,000	87,000	433,000	301,000	350,000
Total net revenue	33,586,000	31,929,000	30,677,000	29,907,000	29,072,000	28,009,000	27,353,000	26,064,000	126,099,000	110,498,000	98,386,000
Selected costs and expenses [Abstract]
Cost of goods sold	11,542,000	10,291,000	10,283,000	9,583,000	9,724,000	9,197,000	8,538,000	8,697,000	41,699,000	36,156,000	32,561,000
Operating earnings	5,312,000	5,213,000	5,031,000	4,371,000	4,731,000	4,020,000	4,442,000	2,904,000	19,927,000	16,097,000	15,905,000
Net earnings	$4,160,000	$2,570,000	$3,205,000	$2,799,000	$3,537,000	$2,672,000	$2,808,000	$2,125,000	$12,734,000	$11,142,000	$9,909,000
Basic net earnings per share (in dollars per share)	$0.25	$0.15	$0.19	$0.17	$0.21	$0.16	$0.17	$0.13	$0.75	$0.68	$0.62
Diluted net earnings per share (in dollars per share)	$0.23	$0.15	$0.18	$0.16	$0.20	$0.16	$0.17	$0.13	$0.72	$0.65	$0.60

Subsequent_Events_Details

Subsequent Events (Details)	Jan. 31, 2015
	sqft
Subsequent Events [Abstract]
Number of square-feet in the buildings acquired	26,000
Number of square-feet in the buildings occupied by the company	17,500
Number of square-feet in the buildings occupied by an existing tenant	8,500

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$200,000	$185,000	$150,000
Additions Charged to Costs and Expenses	250,000	110,000	120,000
Less Deductions	-150,000	-95,000	-85,000
Balance at End of Year	300,000	200,000	185,000
Sales Return Allowance [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	50,000	55,000	30,000
Additions Charged to Costs and Expenses	65,000	20,000	45,000
Less Deductions	-35,000	-25,000	-20,000
Balance at End of Year	80,000	50,000	55,000
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	150,000	130,000	120,000
Additions Charged to Costs and Expenses	185,000	90,000	75,000
Less Deductions	-115,000	-70,000	-65,000
Balance at End of Year	$220,000	$150,000	$130,000